<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Mol Biosci</journal-id><journal-id journal-id-type="iso-abbrev">Front Mol Biosci</journal-id><journal-id journal-id-type="pmc-domain-id">2732</journal-id><journal-id journal-id-type="pmc-domain">fmolb</journal-id><journal-id journal-id-type="publisher-id">Front. Mol. Biosci.</journal-id><journal-title-group><journal-title>Frontiers in Molecular Biosciences</journal-title></journal-title-group><issn pub-type="epub">2296-889X</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC7983051</article-id><article-id pub-id-type="pmcid-ver">PMC7983051.1</article-id><article-id pub-id-type="pmcaid">7983051</article-id><article-id pub-id-type="pmcaiid">7983051</article-id><article-id pub-id-type="pmid">33763450</article-id><article-id pub-id-type="doi">10.3389/fmolb.2021.604447</article-id><article-id pub-id-type="publisher-id">604447</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Molecular Biosciences</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Emerging Therapeutic Approaches to Combat COVID-19: Present Status and Future Perspectives</article-title><alt-title alt-title-type="left-running-head">Vivekanandhan et al.</alt-title><alt-title alt-title-type="right-running-head">Therapeutic Approaches to Combat COVID-19</alt-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Vivekanandhan</surname><given-names initials="K">Karthik</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1235432/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shanmugam</surname><given-names initials="P">Poornima</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1234351/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Barabadi</surname><given-names initials="H">Hamed</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://loop.frontiersin.org/people/527080/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Arumugam</surname><given-names initials="V">Vigneshwaran</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://loop.frontiersin.org/people/1083402/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Daniel Raj Daniel Paul Raj</surname><given-names initials="D">Dharun</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://loop.frontiersin.org/people/1083278/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sivasubramanian</surname><given-names initials="M">Manikandan</given-names></name><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ramasamy</surname><given-names initials="S">Subbaiya</given-names></name><xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://loop.frontiersin.org/people/1209132/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Anand</surname><given-names initials="K">Krishnan</given-names></name><xref ref-type="aff" rid="aff7">
<sup>7</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://loop.frontiersin.org/people/1077037/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Boomi</surname><given-names initials="P">Pandi</given-names></name><xref ref-type="aff" rid="aff8">
<sup>8</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://loop.frontiersin.org/people/1046273/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chandrasekaran</surname><given-names initials="B">Balakumar</given-names></name><xref ref-type="aff" rid="aff9">
<sup>9</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://loop.frontiersin.org/people/1008807/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Arokiyaraj</surname><given-names initials="S">Selvaraj</given-names></name><xref ref-type="aff" rid="aff10">
<sup>10</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://loop.frontiersin.org/people/1151336/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Saravanan</surname><given-names initials="M">Muthupandian</given-names></name><xref ref-type="aff" rid="aff11">
<sup>11</sup>
</xref><xref ref-type="aff" rid="aff12">
<sup>12</sup>
</xref><xref ref-type="corresp" rid="c001">*</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://loop.frontiersin.org/people/823285/overview"/></contrib></contrib-group><aff id="aff1">
<label><sup>1</sup></label>Department of Biotechnology, K. S. Rangasamy College of Technology, Tiruchengode, <addr-line>Tamilnadu</addr-line>, <country>India</country>
</aff><aff id="aff2">
<label><sup>2</sup></label>Department of Pharmaceutical Biotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, <addr-line>Tehran</addr-line>, <country>Iran</country>
</aff><aff id="aff3">
<label><sup>3</sup></label>School of Biosciences and Technology, Vellore Institute of Technology, <addr-line>Vellore</addr-line>, <country>India</country>
</aff><aff id="aff4">
<label><sup>4</sup></label>Department of Biotechnology, Maulana Abul Kalam Azad University of Technology, <addr-line>Haringhata</addr-line>, <country>India</country>
</aff><aff id="aff5">
<label><sup>5</sup></label>Department of Biotechnology, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences (SIMATS), <addr-line>Chennai</addr-line>, <country>India</country>
</aff><aff id="aff6">
<label><sup>6</sup></label>Department of Biological Sciences, School of Mathematics and Natural Sciences, The Copperbelt University, <addr-line>Riverside</addr-line>, <country>Zambia</country>
</aff><aff id="aff7">
<label><sup>7</sup></label>Department of Chemical Pathology, School of Pathology, Faculty of Health Sciences and National Health Laboratory Service, University of the Free State, <addr-line>Bloemfontein</addr-line>, <country>South Africa</country>
</aff><aff id="aff8">
<label><sup>8</sup></label>Department of Bioinformatics, Alagappa University, <addr-line>Karaikudi</addr-line>, <country>India</country>
</aff><aff id="aff9">
<label><sup>9</sup></label>Faculty of Pharmacy, Philadelphia University, <addr-line>Amman</addr-line>, <country>Jordan</country>
</aff><aff id="aff10">
<label><sup>10</sup></label>Department of Food Science and Biotechnology, Sejong University, <addr-line>Seoul</addr-line>, <country>South Korea</country>
</aff><aff id="aff11">
<label><sup>11</sup></label>Department of Microbiology and Immunology, Division of Biomedical Science, School of Medicine, College of Health Science, Mekelle University, <addr-line>Mekelle</addr-line>, <country>Ethiopia</country>
</aff><aff id="aff12">
<label><sup>12</sup></label>AMR and Nanomedicine Laboratory, Department of Pharmacology, Saveetha Dental College, Saveetha Institute of Medical and Technical Sciences (SIMATS), <addr-line>Chennai</addr-line>, <country>India</country>
</aff><author-notes><fn fn-type="edited-by"><p>
<bold>Edited by:</bold>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/187366/overview">Binod Kumar</ext-link>, Loyola University Chicago, United States</p></fn><fn fn-type="edited-by"><p>
<bold>Reviewed by:</bold>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/127405/overview">Krishna Mohan Poluri</ext-link>, Indian Institute of Technology Roorkee, India</p><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/887890/overview">Atoshi Banerjee</ext-link>, University of Nevada, Las Vegas, United States</p></fn><corresp id="c001">*Correspondence: Muthupandian Saravanan, <email>bioinfosaran@gmail.com</email>, <email>saravanan.muthupandian@mu.edu.et</email></corresp><fn fn-type="other"><p>This article was submitted to Molecular Diagnostics and Therapeutics, a section of the journal Frontiers in Molecular Biosciences</p></fn></author-notes><pub-date pub-type="epub"><day>08</day><month>3</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>8</volume><issue-id pub-id-type="pmc-issue-id">375432</issue-id><elocation-id>604447</elocation-id><history><date date-type="received"><day>09</day><month>9</month><year>2020</year></date><date date-type="accepted"><day>22</day><month>1</month><year>2021</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>01</month><year>2021</year></date></event><event event-type="pmc-live"><date><day>23</day><month>03</month><year>2021</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-11-10 07:25:09.333"><day>10</day><month>11</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2021 Vivekanandhan, Shanmugam, Barabadi, Arumugam, Daniel Raj Daniel Paul Raj, Sivasubramanian, Ramasamy, Anand, Boomi, Chandrasekaran, Arokiyaraj and Saravanan.</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Vivekanandhan, Shanmugam, Barabadi, Arumugam, Daniel Raj Daniel Paul Raj, Sivasubramanian, Ramasamy, Anand, Boomi, Chandrasekaran, Arokiyaraj and Saravanan</copyright-holder><license xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fmolb-08-604447.pdf"/><abstract><p>Coronavirus disease (COVID-19) has emerged as a fast-paced epidemic in late 2019 which is disrupting life-saving immunization services. SARS-CoV-2 is a highly transmissible virus and an infectious disease that has caused fear among people across the world. The worldwide emergence and rapid expansion of SARS-CoV-2 emphasizes the need for exploring innovative therapeutic approaches to combat SARS-CoV-2. The efficacy of some antiviral drugs such as remdesivir, favipiravir, umifenovir, etc., are still tested against SARS-CoV-2. Additionally, there is a large global effort to develop vaccines for the protection against COVID-19. Because vaccines seem the best solution to control the pandemic but time is required for its development, pre-clinical/clinical trials, approval from FDA and scale-up. The nano-based approach is another promising approach to combat COVID-19 owing to unique physicochemical properties of nanomaterials. Peptide based vaccines emerged as promising vaccine candidates for SARS-CoV-2. The study emphasizes the current therapeutic approaches against SARS-CoV-2 and some of the potential candidates for SARS-CoV-2 treatment which are still under clinical studies for their effectiveness against SARS-CoV-2. Overall, it is of high importance to mention that clinical trials are necessary for confirming promising drug candidates and effective vaccines and the safety profile of the new components must be evaluated before translation of <italic toggle="yes">in vitro</italic> studies for implementation in clinical use.</p></abstract><kwd-group><kwd>COVID-19</kwd><kwd>SARS-CoV-2</kwd><kwd>therapeutics</kwd><kwd>antiviral drugs</kwd><kwd>vaccines</kwd><kwd>nano-based approaches</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1"><title>Introduction</title><p>The COVID-19 outbreak made the entire world frightened in late 2019, which is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) belongs to single stranded RNA viruses having spike-like projections of glycoprotein. The virus infection was first reported in Wuhan, People&#8217;s Republic of China during December 2019 (<xref rid="B19" ref-type="bibr">Chen et al., 2020</xref>). COVID-19 is the official name of the coronavirus declared by the World Health Organization (WHO). Even though the source of coronavirus has not been declared officially, bats and snakes are considered as the potential host. Wuhan institute of virology confirmed that 96% of similarity coronavirus with the gene sequence of bat coronavirus (<xref rid="B72" ref-type="bibr">Wang W. et al., 2020</xref>; <xref rid="B86" ref-type="bibr">Zhou P. et al., 2020</xref>). Coronavirus infects humans via the binding of S-protein with angiotensin-converting enzyme-2 (ACE-2) with higher affinity (<xref rid="B79" ref-type="bibr">Wrapp et al., 2020</xref>). Transmission of coronavirus is through respiratory droplets of infected persons. The common symptoms include fever, throat infection, cough, headache and breathlessness even some may be asymptomatic. The average incubation period of coronavirus ranges from three days to twenty-four days (<xref rid="B28" ref-type="bibr">Guan et al., 2020</xref>; <xref rid="B87" ref-type="bibr">Zhou et al., 2020a</xref>) but the prevalence is more in elderly people with medical comorbidities.</p><p>During this pandemic outbreak, several countries adopt preventive measures and their own treatment methodologies. Avoiding contact with infected persons, unnecessary travel and personal hygiene practices are the basic preventive measures followed to avoid the transmission of coronavirus. RT-PCR and chest computed tomography scan are the diagnostic tools used along with the combination of symptom relevant treatment (<xref rid="B69" ref-type="bibr">Velavan and Meyer, 2020</xref>). Viral infections are the major threat to the human kind. As of now, antiviral therapy, symptomatic and oxygen therapy are followed for treating SARS-CoV-2. Nano-based approaches are the promising tool for the diagnosis and treatment of such viral diseases. Based on the statistical analysis of StatNano, out of patents filed related to SARS-CoV-2 diagnostics and treatments, 5.2% belong to nano-based technology (<xref rid="B16" ref-type="bibr">Chakravarthy and Vora, 2020</xref>). With this background, the present review focuses on emerging approaches including drug repurposing, vaccine development including peptide and nano based approaches for COVID-19 therapeutics.</p></sec><sec id="s2"><title>Emerging Approaches for COVID-19 Therapeutics</title><sec id="s2-1"><title>Drug Repurposing Approach for COVID-19 Treatment</title><p>Even though a lot of potential antiviral drugs are available, their efficacy against SARS-CoV-2 is still tested for implementation. Below discussed drugs are some of the potential candidates for COVID-19 treatment and are under clinical study. <xref ref-type="fig" rid="F1">Figure 1</xref> depicts the schematic illustration of drug repurposing approach.</p><fig id="F1" position="float" orientation="portrait"><label>FIGURE 1</label><caption><p>A schematic illustration of drug repurposing approach.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fmolb-08-604447-g001.jpg"/></fig><sec id="s2-1-1"><title>Remdesivir</title><p>Remdesivir, developed by Gilead Sciences (2009), is a broad-spectrum antiviral agent with a brand name of &#8220;veklury&#8221; administered as an intravenous injection. It was initially designed for Hepatitis C (Hep C) and respiratory syncytial virus (RSV). Later it was repurposed against Ebola and Marburg virus. Remdesivir has antiviral activity against filoviruses, pneumoviruses, paramyxoviruses, and coronaviruses <italic toggle="yes">in vitro</italic> (<xref rid="B46" ref-type="bibr">Lo and Jordan, 2017</xref>). Remdesivir, being an analogue of nucleotide, in its triphosphate form, i.e., Remdesivir triphosphate (RDV-TP), is used as a substrate for RNA dependent RNA polymerase, and has reported to inhibit the viral RNA synthesis by delayed termination of synthesis (<xref rid="B71" ref-type="bibr">Wang M. et al., 2020</xref>) in all corona viruses, including SARS-CoV-2. It was seen that RDV-TP resembles ATP (Adenosine triphosphate) (<xref rid="B58" ref-type="bibr">Saha et al., 2020</xref>). It competes with viral RNA synthesis, by forming a phosphodiester bond with the next nucleotide and terminates viral RNA formation at the third site from RDV-TP binding site, causing the termination of viral RNA synthesis in SARS-CoV-2 (<xref rid="B27" ref-type="bibr">Gordon et al., 2020</xref>).</p><p>Remdesivir exhibited an <italic toggle="yes">in vitro</italic> activity against SARS-CoV-2 in a preclinical study using <italic toggle="yes">Rhesus macaque</italic> model of SARS-CoV-2, the treatment was initiated soon after the <italic toggle="yes">Rhesus macaque</italic> was inoculated with SARS-CoV-2, and group of <italic toggle="yes">Rhesus macaque</italic> treated with remdesivir showed lower virus levels than untreated (<xref rid="B76" ref-type="bibr">Williamson et al., 2020</xref>). The toxicity and adverse effect of remdesivir is not clear yet and is to be investigated further (<xref rid="B26" ref-type="bibr">Fan et al., 2020</xref>). In clinical trials, remdesivir does not show gastrointestinal toxicity apart from minor diarrhoea in a few cases. In case of hepatotoxicity, elevations in the aminotransferases were noticed. In the case of nephrotoxicity, upon continual doses of remdesivir, reduced kidney function was observed. In case of respiratory toxicity, acute respiratory syndrome was observed in 4% of the patients treated with remdesivir.</p><p>The recommendation for the use of remdesivir arose from the multicentre, randomized placebo-controlled trials and the adaptive SARS-CoV-2 treatment trial (ACTT) (<xref rid="B71" ref-type="bibr">Wang M. et al., 2020</xref>). The study was conducted across 1603 SARS-CoV-2 infected patients. The patients in the trial group were affected to an extent that they require oxygen supplement, but mechanical ventilation (ECMO) is not required and the recovery period of 10&#8211;15 days was observed (<xref rid="B10" ref-type="bibr">Beigel et al., 2020</xref>). It is currently approved for treatment in the United States, India, Taiwan, Singapore and many other countries.</p></sec><sec id="s2-1-2"><title>Hydroxychloroquine</title><p>Chloroquine is an anti-malarial drug developed in 1934. Later in 1946 hydroxychloroquine (HCQ), an analogue of chloroquine was developed to treat autoimmune diseases. HCQ has been used for the treatment of lupus, erythematosus, Q fever, certain types of malaria and rheumatoid arthritis (American society of health system pharmacist 2020). HCQ has fewer and less severe toxicities (including less propensity to prolong the QTc interval) and fewer drug-drug interactions than chloroquine. Studies show that HCQ increases the endosomal pH inhibiting fusion of SARS-CoV-2 with the host cell membrane (<xref rid="B71" ref-type="bibr">Wang M. et al., 2020</xref>). They possess an immunomodulatory effect and also block the transport of SARS-CoV-2 from early endosomes to endolysosomes, which may be required for the release of viral genome (<xref rid="B44" ref-type="bibr">Liu et al., 2020</xref>).</p><p>Most deaths in SARS-CoV-2 patients occurred due to cytokine storms. Cytokines play an important role in normal immune responses, but releasing large amounts in the body all at once can be harmful. A cytokine storm can occur as a result of an infection, autoimmune condition, or other diseases. It is observed that HCQ can reduce cytokine storms (<xref rid="B14" ref-type="bibr">Cao, 2020</xref>). A recent study by <xref rid="B67" ref-type="bibr">Tang et al., (2020b)</xref> reported that HCQ reduced clinical symptoms through anti-inflammatory properties and recovery of lymphopenia. But still safety, side effects and effectiveness of HCQ are under study. Further, the benefits and risks associated with HCQ depends on patient medical history (<xref rid="B35" ref-type="bibr">Juurlink 2020</xref>).</p><p>FDA has approved the use of 800&#160;mg (HCQ) on the first day, followed by 400&#160;mg for the next seven days for COVID-19 treatment (US FDA &#8211; Hydroxychloroquinone fact sheet for patients). Higher dosage leads to arrhythmia and sometimes eventual death (<xref rid="B93" ref-type="bibr">Borba et al., 2020</xref>). Patients with a history of renal and liver disorders should be treated with care using HCQ as it leads to nephrotoxicity and hepatotoxicity (<xref rid="B57" ref-type="bibr">Rismanbaf and Zarei, 2020</xref>).</p></sec><sec id="s2-1-3"><title>Lopinavir/Ritonavir</title><p>Lopinavir/Ritonavir, under the brand name Kaletra<sup>&#174;</sup>, belong to the protease inhibitor class which is especially used in the treatment of retroviruses which helps in SARS-CoV-2 treatment (<xref rid="B57" ref-type="bibr">Rismanbaf and Zarei, 2020</xref>). Although it is not curing HIV, it prevents secondary infections by decreasing the viral count, which are the characteristic symptoms of acquired immune-deficiency syndrome. Replication of SARS-CoV-2 depends on the cleavage of a poly protein into a RNA-dependent RNA polymerase and helicase, which helps in replicating the viral genome in the host cells (<xref rid="B88" ref-type="bibr">Zumla et al., 2016</xref>). For the cleavage of the poly protein, two proteases enzymes including 3-chymotrypsin-like protease (3CLpro) and papain-like protease (PLpro) are responsible, found in SARS-CoV-2 (<xref rid="B65" ref-type="bibr">Tahir ul Qamar et al., 2020</xref>). Thus, protease inhibitors like lopinavir and ritonavir reduce the viral count in the infected person&#8217;s body system and help them in recovery. In an <italic toggle="yes">In vitro</italic> study, it was found that lopinavir/ritonavir inhibited the protease 3CLpro (<xref rid="B43" ref-type="bibr">Liu and Wang, 2020</xref>; <xref rid="B44" ref-type="bibr">Liu et al., 2020</xref>).</p><p>In a clinical research study with a sample size of 199 patients, the patients were given Lopinavir 400/Ritonavir 100&#160;mg orally, twice a day. It was observed that the group which was under liponavir/ritonavir treatment, recovered with a shorter intensive care time rather than the untreated group, and also the rate of mortality was less, though it was not statistically significant (<xref rid="B13" ref-type="bibr">Cao et al., 2020</xref>). Most clinical studies that surround lopinavir and ritonavir have a very small sample size, but it has been approved for treatment by National institute of Health (NIH) United States. The use of lopinavir/ritonavir is not recommended for patients suffering from porphyria, cardiac problems and cardiac conduction problems. Other side effects on usage are diarrhoea, which might persist for a week after usage. In some cases, diabetes mellitus, pancreatitis and hepatic problems have been reported as side effects due to the administering of lopinavir/ritonavir (<xref rid="B33" ref-type="bibr">Joint Formulary Committee, 2020</xref>).</p></sec><sec id="s2-1-4"><title>Umifenovir</title><p>Umifenovir, developed in Russia and China has been used for infections caused by Influenza A, B and prophylaxis. The main mode of action by umifenovir is blocking the fusion of virus to the cell/endosome by interfering with the hydrogen bond network in the phospholipid (<xref rid="B70" ref-type="bibr">Villalain, 2010</xref>). <italic toggle="yes">In vitro</italic> study on the effect of Umifenovir against SARS-CoV-1 and SARS-CoV-2 revealed that Umifenovir combined with protease inhibitor (Liponavir/Ritonavir) exhibited higher negative conversion rates (<xref rid="B22" ref-type="bibr">Deng et al., 2020</xref>). But the latter is superior in terms of faster recovery (<xref rid="B17" ref-type="bibr">Chang et al., 2020</xref>).</p><p>Though Umifenovir did not exhibit severe adverse side effects, gastric problems including digestion, diarrhoea and nausea are reported (<xref rid="B29" ref-type="bibr">Huang et al., 2020</xref>). Further, there is no report on nephrotoxicity or hepatotoxicity. But some clinical studies have declared that umifenovir is not effective against SARS-CoV-2 treatment (<xref rid="B29" ref-type="bibr">Huang et al., 2020</xref>). Based on a clinical study conducted in Jinyintan Hospital, Wuhan province, it was revealed that Umifenovir neither increases the clearance rate of SARS-CoV-2 nor accelerates the recovery of patients in any way (<xref rid="B41" ref-type="bibr">Lian et al., 2020</xref>). The effect of umifenovir in SARS-CoV-2 treatment, still requires clinical investigations for further understanding.</p></sec><sec id="s2-1-5"><title>Favipiravir</title><p>Favipiravir was first developed in 2014 by Fujifilm Toyama Chemical Co. Ltd., Japan, for the treatment of a novel influenza strain that was resistant to neuraminidase inhibitors. It is an analogue of guanine with a pyrazine carboxamide structure. Favipiravir enters the infected cell by endocytosis, and at the site it is transformed into favipiravir ribofuranosyl phosphate via phosphoribosylation and phosphorylation. After transformation, the prodrug destroys the conservative catalytic domain of RNA-dependent RNA polymerase (RdRp), interrupting the nucleotide incorporation process, thus interfering with the life cycle of the virus and hindering its replication within the host cell.</p><p>The RdRp of SARS-CoV-2 is 10X more active than any other viral RdRp faced until now (<xref rid="B60" ref-type="bibr">Shanon et al., 2020</xref>). Favipiravir is highly recommended as it inhibits viral RNA by sparing the native DNA of the host cell. <xref rid="B17" ref-type="bibr">Chang et al., (2020)</xref> conducted a clinical trial on the effectiveness of favipiravir and umifenovir against SARS-CoV-2. The study revealed that the recovery rate in favipiravir was higher than umifenovir. <xref rid="T1" ref-type="table">Table 1</xref> shows the mode of action of potential antiviral drugs repurposed for COVID-19.</p><table-wrap id="T1" position="float" orientation="portrait"><label>TABLE 1</label><caption><p>Mode of action of potential antiviral drugs repurposed for COVID-19.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="left" rowspan="1" colspan="1">Drug</th><th align="center" rowspan="1" colspan="1">Mode of action</th><th align="center" rowspan="1" colspan="1">References</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="1" colspan="1">Remdesivir</td><td align="left" rowspan="1" colspan="1">Binds to the viral-RNA dependent RNA polymerase, inhibiting the replication of the virus by terminating transcription of viral-RNA</td><td align="left" rowspan="1" colspan="1">
<xref rid="B77" ref-type="bibr">Wit, (2020)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Hydroxychloroquine</td><td align="left" rowspan="1" colspan="1">Increases the endosomal pH inhibiting the fusion of SARS-CoV-2 with the host cell membrane</td><td align="left" rowspan="1" colspan="1">
<xref rid="B66" ref-type="bibr">Tang et al. (2020a)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Lopinavir/Ritonavir</td><td align="left" rowspan="1" colspan="1">Inhibits the protein 3CLpro, required for cleaving poly protein into RNA dependent RNA polymerase and helicase, helps in transcription of Viral RNA.</td><td align="left" rowspan="1" colspan="1">
<xref rid="B13" ref-type="bibr">Cao et al. (2020)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Umifenovir</td><td align="left" rowspan="1" colspan="1">Blocks the fusion of virus to the cell/endosome by interfering with the hydrogen bond network in the phospholipid</td><td align="left" rowspan="1" colspan="1">
<xref rid="B41" ref-type="bibr">Lian et al. (2020)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Favipiravir</td><td align="left" rowspan="1" colspan="1">Destroys the conservative catalytic domain of RNA-dependent RNA polymerase (RdRp), interrupting the nucleotide incorporation process, thus interfering with the life cycle of the virus</td><td align="left" rowspan="1" colspan="1">
<xref rid="B60" ref-type="bibr">Shannon et al. (2020)</xref>
</td></tr></tbody></table></table-wrap><p>Treatment with favipiravir causes hyperuricemia. The major adverse effects on use of favipiravir is teratogenicity. Teratogenicity is the phenomenon where some agents (teratogens) cause major birth defects. Thus, the use of favipiravir of women at the child bearing age or pregnant ladies is highly inadvisable. Even men treated with favipiravir are advised to use contraceptive for a week minimum or until favipiravir is out of the system, to avoid any teratogenicity (Evaluation and Licensing Division, <xref rid="B54" ref-type="bibr">Pharmaceutical and Food Safety Bureau., 2011</xref>. Report on the Deliberation Results&#8212;Avigan.)</p></sec></sec><sec id="s2-2"><title>Vaccine Development Approach</title><p>Vaccine development involves different strategies including live attenuated, or inactivated virus, virus-like particles or other protein-based approaches, viral vector&#8211;based vaccines or nucleic acid&#8211;based vaccines (<xref rid="B18" ref-type="bibr">Chauhan et al., 2020</xref>). In live attenuated vaccines, virulence of the virus is removed but viability is retained which in turn helps the immune system to develop memory cells (<xref rid="B7" ref-type="bibr">Badgett et al., 2002</xref>). Virus-like particles are molecules that closely resemble viruses which are synthesized by the expression of the viral structural protein. The synthesized molecules can assemble themselves to virus-like particles and help the body to boost immunity (<xref rid="B84" ref-type="bibr">Zeltins 2013</xref>). Viral vector-based vaccines and nucleic acid-based vaccines, incorporate the antibody expressing gene into the cell to produce necessary antibodies to acquire immunity against infections. Drug discovery and development for SARS-CoV-2 can be facilitated by artificial intelligence and other computational tools (<xref rid="B67" ref-type="bibr">Tang et al., 2020b</xref>; <xref rid="B43" ref-type="bibr">Lin et al., 2020</xref>; <xref rid="B90" ref-type="bibr">Zhou et al., 2020b</xref>). Adjuvants such as MF59, AS03, CpG are considered for COVID-19 treatment (<xref rid="B18" ref-type="bibr">Chauhan et al., 2020</xref>) to enhance the vaccine efficacy (<xref rid="B74" ref-type="bibr">Weinberger, 2018</xref>).</p><p>Lipid nanoparticles (<xref rid="B4" ref-type="bibr">Adams et al., 2018</xref>), lipid coated mesoporous silica nanoparticles (<xref rid="B39" ref-type="bibr">LaBauve et al., 2018</xref>), Macrophage mimetic nanoparticles (MMNPs) (<xref rid="B85" ref-type="bibr">Zhang et al., 2020</xref>), Nano-Erythrocyte mimetic drug delivery (<xref rid="B15" ref-type="bibr">Cavezzi et al., 2020</xref>; <xref rid="B55" ref-type="bibr">Poduri et al., 2020</xref>), Nano-Platelet mimetic drug delivery (<xref rid="B6" ref-type="bibr">Anselmo et al., 2014</xref>), Nano-virus mimetic drug delivery (<xref rid="B25" ref-type="bibr">Ellah et al., 2020</xref>) have also been considered for COVID-19 therapeutics. The review includes discussion on peptide and nano based vaccine approaches for COVID-19 therapeutics. A complete list of vaccine candidates developed for COVID-19 is given in <xref ref-type="sec" rid="s7">Supplementary Appendix</xref> (WHO-Draft landscape of COVID-19 candidate vaccines, 2021) (Table 4). <xref ref-type="fig" rid="F2">Figure 2</xref> depicts schematic illustration of vaccine development approach.</p><fig id="F2" position="float" orientation="portrait"><label>FIGURE 2</label><caption><p>A schematic illustration of vaccine development approach.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fmolb-08-604447-g002.jpg"/></fig><sec id="s2-2-1"><title>Peptide Based Vaccines</title><p>Peptide based vaccines are biologically safe and need not to be produced <italic toggle="yes">in vitro</italic>. Peptide vaccines outweigh the limitations of conventional vaccines by overcoming allergic reactions and autoimmune responses (<xref rid="B40" ref-type="bibr">Li et al., 2014</xref>). Peptide based vaccines are engineered to mimic the proteins or peptides in the pathogens, which can help in developing T-cells which are immunodominant (<xref rid="B48" ref-type="bibr">Malonis et al., 2020</xref>). Synthetic peptide vaccines are usually short amino acid sequences (20&#8211;30 amino acids in range) mimicking the specific epitope of the antigen of pathogen. B cells can recognize the mimicked peptide sequence and produce antibodies. T killer cells also kick in fast as the body responds by peptide based vaccine. Antibodies produced during infection target multiple antigen sites and over time some antibodies target specific antigen epitopes for immunity development. Bioinformatics tools facilitate finding the accessible peptide residue sites and a specific peptide can be engineered to bind the site. These tools help to narrow down to SARS-CoV-2-RBD (SARS-CoV-2-Receptor Binding Domain) to interact with hACE2 gaining entry to viral attachment and re-entry (<xref rid="B9" ref-type="bibr">Barh et al., 2020</xref>; <xref rid="B85" ref-type="bibr">Zhang et al., 2020</xref>).</p><p>Peptide derived from fermented soy cheese using <italic toggle="yes">Lactobacillus delbrueckii</italic> WS4 can be used as a potential antiviral agent for SARS CoV-2 (<xref rid="B20" ref-type="bibr">Chourasia et al., 2020</xref>). Peptide vaccine developed by IMV Inc., used DPX platform (<xref rid="B82" ref-type="bibr">Ye et al., 2020</xref>). Vaxil corporation developed signal peptide (<xref rid="B80" ref-type="bibr">Wu, 2020</xref>). Epivax and Generex Biotechnology Corporation proposed hybrid based Ii-Key peptide vaccine (<xref rid="B37" ref-type="bibr">Kallinters et al., 2020</xref>). Epivax proposed adjuvating peptide vaccines also (<xref rid="B80" ref-type="bibr">Wu, 2020</xref>). <xref rid="T2" ref-type="table">Table 2</xref> shows the detailed list of peptide based vaccines developed for COVID-19 with platform description and developer.</p><table-wrap id="T2" position="float" orientation="portrait"><label>TABLE 2</label><caption><p>Peptide based vaccines developed for COVID-19.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="left" rowspan="1" colspan="1">Vaccine platform description</th><th align="center" rowspan="1" colspan="1">Developers</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="1" colspan="1">RBD protein delivered in mannose-conjugated chitosan nanoparticle</td><td align="left" rowspan="1" colspan="1">Ohio State University/Kazakh National Agrarian University</td></tr><tr><td align="left" rowspan="1" colspan="1">Recombinant spike protein with Essai O/W 1849101 adjuvant</td><td align="left" rowspan="1" colspan="1">Kazakh National Agrarian University</td></tr><tr><td align="left" rowspan="1" colspan="1">Peptides</td><td align="left" rowspan="1" colspan="1">Neo7Logic</td></tr><tr><td align="left" rowspan="1" colspan="1">Recombinant spike protein with Essai O/W 1849101 adjuvant</td><td align="left" rowspan="1" colspan="1">Kazakh National Agrarian University, Kazakhstan/National Scientific Center for Especially Dangerous Infections</td></tr><tr><td align="left" rowspan="1" colspan="1">Recombinant S protein</td><td align="left" rowspan="1" colspan="1">Max-Planck-Institute of Colloids and Interfaces</td></tr><tr><td align="left" rowspan="1" colspan="1">RBD protein (baculovirus production) + FAR-Squalene adjuvant</td><td align="left" rowspan="1" colspan="1">Farmacol&#243;gicos Veterinarios SAC (FARVET SAC)/Universidad Peruana Cayetano Heredia (UPCH)</td></tr><tr><td align="left" rowspan="1" colspan="1">Protein Subunit</td><td align="left" rowspan="1" colspan="1">Research Institute for Biological Safety Problems, Rep of Kazakhstan</td></tr><tr><td align="left" rowspan="1" colspan="1">RBD-protein</td><td align="left" rowspan="1" colspan="1">Mynvax</td></tr><tr><td align="left" rowspan="1" colspan="1">Recombinant S protein</td><td align="left" rowspan="1" colspan="1">Izmir Biomedicine and Genome Center</td></tr><tr><td align="left" rowspan="1" colspan="1">Peptide + novel adjuvant</td><td align="left" rowspan="1" colspan="1">Bogazici University</td></tr><tr><td align="left" rowspan="1" colspan="1">S subunit intranasal liposomal formulation with GLA/3M052 adjs.</td><td align="left" rowspan="1" colspan="1">University of Virginia</td></tr><tr><td align="left" rowspan="1" colspan="1">S-Protein (Subunit) + Adjuvant, <italic toggle="yes">E coli</italic> based Expression</td><td align="left" rowspan="1" colspan="1">Helix Biogen Consult, Ogbomoso and Trinity Immonoefficient Laboratory, Ogbomoso, Oyo State, Nigeria</td></tr><tr><td align="left" rowspan="1" colspan="1">Protein Subunit S,N,M&amp;S1 protein</td><td align="left" rowspan="1" colspan="1">National Research Centre, Egypt</td></tr><tr><td align="left" rowspan="1" colspan="1">Protein Subunit</td><td align="left" rowspan="1" colspan="1">University of San Martin and CONICET, Argentina</td></tr><tr><td align="left" rowspan="1" colspan="1">RBD protein fused with Fc of IgG + Adj.</td><td align="left" rowspan="1" colspan="1">Chulalongkorn University/GPO, Thailand</td></tr><tr><td align="left" rowspan="1" colspan="1">Capsid-like Particle</td><td align="left" rowspan="1" colspan="1">AdaptVac (PREVENT-nCoV consortium)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">Drosophila</italic> S2 insect cell expression system VLPs</td><td align="left" rowspan="1" colspan="1">ExpreS2ion</td></tr><tr><td align="left" rowspan="1" colspan="1">Peptide antigens formulated in LNP</td><td align="left" rowspan="1" colspan="1">IMV Inc</td></tr><tr><td align="left" rowspan="1" colspan="1">S Protein</td><td align="left" rowspan="1" colspan="1">WRAIR/USAMRIID</td></tr><tr><td align="left" rowspan="1" colspan="1">S Protein + Adjuvant</td><td align="left" rowspan="1" colspan="1">National Institute of Infectious Disease, Japan/Shionogi/UMN Pharma</td></tr><tr><td align="left" rowspan="1" colspan="1">VLP-recombinant protein + Adjuvant</td><td align="left" rowspan="1" colspan="1">Osaka University/BIKEN/National Institutes of Biomedical Innovation, Japan</td></tr><tr><td align="left" rowspan="1" colspan="1">Microneedle arrays S1 subunit</td><td align="left" rowspan="1" colspan="1">Univ. of Pittsburgh</td></tr><tr><td align="left" rowspan="1" colspan="1">Peptide</td><td align="left" rowspan="1" colspan="1">Vaxil Bio</td></tr><tr><td align="left" rowspan="1" colspan="1">Adjuvanted protein subunit (RBD)</td><td align="left" rowspan="1" colspan="1">Biological E Ltd.</td></tr><tr><td align="left" rowspan="1" colspan="1">Peptide</td><td align="left" rowspan="1" colspan="1">Flow Pharma Inc</td></tr><tr><td align="left" rowspan="1" colspan="1">S Protein</td><td align="left" rowspan="1" colspan="1">AJ Vaccines</td></tr><tr><td align="left" rowspan="1" colspan="1">Ii-Key peptide</td><td align="left" rowspan="1" colspan="1">Generex/EpiVax</td></tr><tr><td align="left" rowspan="1" colspan="1">S Protein</td><td align="left" rowspan="1" colspan="1">EpiVax/Univ. of Georgia</td></tr><tr><td align="left" rowspan="1" colspan="1">Protein Subunit EPV-CoV-19</td><td align="left" rowspan="1" colspan="1">EpiVax</td></tr><tr><td align="left" rowspan="1" colspan="1">gp-96 backbone</td><td align="left" rowspan="1" colspan="1">Heat Biologics/Univ. Of Miami</td></tr><tr><td align="left" rowspan="1" colspan="1">Subunit vaccine</td><td align="left" rowspan="1" colspan="1">FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo</td></tr><tr><td align="left" rowspan="1" colspan="1">S1 or RBD protein</td><td align="left" rowspan="1" colspan="1">Baylor College of Medicine</td></tr><tr><td align="left" rowspan="1" colspan="1">Subunit protein, plant produced</td><td align="left" rowspan="1" colspan="1">iBio/CC-Pharming</td></tr><tr><td align="left" rowspan="1" colspan="1">Recombinant protein, nanoparticles (based on S-protein and other epitopes)</td><td align="left" rowspan="1" colspan="1">Saint-Petersburg scientific research institute of vaccines and serums</td></tr><tr><td align="left" rowspan="1" colspan="1">COVID-19 XWG-03 truncated S proteins</td><td align="left" rowspan="1" colspan="1">Innovax/Xiamen Univ./GSK</td></tr><tr><td align="left" rowspan="1" colspan="1">Adjuvanted microsphere peptide</td><td align="left" rowspan="1" colspan="1">VIDO-InterVac, University of Saskatchewan</td></tr><tr><td align="left" rowspan="1" colspan="1">Synthetic Long Peptide Vaccine candidate for S and M proteins</td><td align="left" rowspan="1" colspan="1">OncoGen</td></tr><tr><td align="left" rowspan="1" colspan="1">Oral E. coli-based protein expression system of S and N proteins</td><td align="left" rowspan="1" colspan="1">MIGAL Galilee Research Institute</td></tr><tr><td align="left" rowspan="1" colspan="1">Nanoparticle vaccine</td><td align="left" rowspan="1" colspan="1">LakePharma, Inc.,</td></tr><tr><td align="left" rowspan="1" colspan="1">Plant-based subunit (RBD-Fc + Adjuvant)</td><td align="left" rowspan="1" colspan="1">Baiya Phytopharm/Chula Vaccine Research Center</td></tr><tr><td align="left" rowspan="1" colspan="1">OMV-based vaccine</td><td align="left" rowspan="1" colspan="1">Quadram Institute Biosciences</td></tr><tr><td align="left" rowspan="1" colspan="1">OMV-based vaccine</td><td align="left" rowspan="1" colspan="1">BiOMViS Srl/Univ. of Trento</td></tr><tr><td align="left" rowspan="1" colspan="1">Structurally modified spherical particles of the tobacco mosaic virus (TMV)</td><td align="left" rowspan="1" colspan="1">Lomonosov Moscow State University</td></tr><tr><td align="left" rowspan="1" colspan="1">Spike-based</td><td align="left" rowspan="1" colspan="1">University of Alberta</td></tr><tr><td align="left" rowspan="1" colspan="1">Recombinant S1-Fc fusion protein</td><td align="left" rowspan="1" colspan="1">AnyGo Technology</td></tr><tr><td align="left" rowspan="1" colspan="1">Recombinant protein</td><td align="left" rowspan="1" colspan="1">Yisheng Biopharma</td></tr><tr><td align="left" rowspan="1" colspan="1">Recombinant S protein in IC-BEVS (Viral vector vaccine (based on baculovirus expression system in insect cell line)</td><td align="left" rowspan="1" colspan="1">Vabiotech, Vietnam and University of Bristol, United Kingdom</td></tr><tr><td align="left" rowspan="1" colspan="1">Orally delivered, heat stable subunit</td><td align="left" rowspan="1" colspan="1">Applied Biotechnology Institute, Inc.,</td></tr><tr><td align="left" rowspan="1" colspan="1">Peptides derived from Spike protein</td><td align="left" rowspan="1" colspan="1">Axon Neuroscience SE</td></tr><tr><td align="left" rowspan="1" colspan="1">Protein Subunit</td><td align="left" rowspan="1" colspan="1">MOGAM Institute for Biomedical Research, GC Pharma</td></tr><tr><td align="left" rowspan="1" colspan="1">RBD-based</td><td align="left" rowspan="1" colspan="1">Neovii/Tel Aviv University</td></tr><tr><td align="left" rowspan="1" colspan="1">Outer Membrane Vesicle (OMV)-subunit</td><td align="left" rowspan="1" colspan="1">Intravacc/Epivax</td></tr><tr><td align="left" rowspan="1" colspan="1">Spike-based (epitope screening)</td><td align="left" rowspan="1" colspan="1">ImmunoPrecise/LiteVax BV</td></tr><tr><td align="left" rowspan="1" colspan="1">Spiked-based</td><td align="left" rowspan="1" colspan="1">Nanografi Nano Technology, Middle East Technical University, Ankara University</td></tr><tr><td align="left" rowspan="1" colspan="1">Recombinant spike with adjuvant</td><td align="left" rowspan="1" colspan="1">Iran</td></tr><tr><td align="left" rowspan="1" colspan="1">Recombinant S protein produced in BEVS</td><td align="left" rowspan="1" colspan="1">Tampere University</td></tr><tr><td align="left" rowspan="1" colspan="1">Protein Subunit Nanoformulated</td><td align="left" rowspan="1" colspan="1">Vaxinano, CEA, INRAE</td></tr><tr><td align="left" rowspan="1" colspan="1">Protein Subunit Adenoviral Carrier</td><td align="left" rowspan="1" colspan="1">CEA, CNRS</td></tr><tr><td align="left" rowspan="1" colspan="1">Protein DC-targeted epitopes</td><td align="left" rowspan="1" colspan="1">LinkinVax, VRI</td></tr></tbody></table></table-wrap></sec><sec id="s2-2-2"><title>Nano Based Therapeutic Approaches</title><p>Nanotechnology plays a major role in COVID-19 therapeutics (<xref rid="B53" ref-type="bibr">Petros and DeSimone, 2010</xref>). The success of nanotechnology in SARS CoV-2 therapeutics depends on the appropriate choice of nanocarriers for the right drug candidate (<xref rid="B18" ref-type="bibr">Chauhan et al., 2020</xref>). Moreover, nanocarriers overcome the limitations of existing antiviral therapies. Nanoparticle aided modulation of antigen presenting cells (APCs) is important for vaccine development in COVID-19 (<xref rid="B8" ref-type="bibr">Banchereau and Steinman 1998</xref>; <xref rid="B64" ref-type="bibr">Steinman and Banchereau, 2007</xref>). During the initial stages of the COVID-19, nano-macrophage mimetic systems neutralize viral activity and in later stages it reduces the inflammation (<xref rid="B85" ref-type="bibr">Zhang et al., 2020</xref>). The effects associated with hematological pathology of COVID-19 can be reduced by Nano-Erythrocyte mimetic drug delivery (<xref rid="B15" ref-type="bibr">Cavezzi et al., 2020</xref>; <xref rid="B55" ref-type="bibr">Poduri et al., 2020</xref>). Thrombocytopenia and vascular damages induced by COVID-19 can be reduced by Nano-Platelet mimetic drug delivery (<xref rid="B6" ref-type="bibr">Anselmo et al., 2014</xref>). The self-amplifying RNA encoding SARS-CoV-2 spike protein was encapsulated in lipid nanoparticles which can act as a vaccine for neutralizing the pseudo-virus (<xref rid="B49" ref-type="bibr">Mckay et al., 2020</xref>) (<xref rid="B62" ref-type="bibr">Shin et al., 2019</xref>). Layered Double Hydroxide (LDH), an inorganic nanoparticle intercalated with short hairpin RNA (shRNA) plasmid has the potential of gene silencing at the target sequence is employed for SARS-CoV-2. Further, it is formulated as a nasal spray for delivering shRNA at the target sites (<xref rid="B3" ref-type="bibr">Acharya, 2020</xref>). The small-interfering RNA (si-RNA) encapsulated in lipidic nano-nanoparticles can be used to inhibit chemokine receptor (CCR2), which is responsible for creating cytokine storms. The cytokine storm is one of the major clinical complications in SARS-CoV-2. The inhibition may result in the reduction of inflammatory sites in the infected regions (<xref rid="B12" ref-type="bibr">Campos et al., 2020</xref>). Peptide based vaccines are also developed using Lipid nanoparticle formulation. <xref rid="T3" ref-type="table">Table 3</xref> shows the nano-based therapeutic options for Coronavirus.</p><table-wrap id="T3" position="float" orientation="portrait"><label>TABLE 3</label><caption><p>Nano based therapeutic options for Coronavirus.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="left" rowspan="1" colspan="1">Nanoparticle</th><th align="center" rowspan="1" colspan="1">Coronavirus antigen</th><th align="center" rowspan="1" colspan="1">Adjuvant</th><th align="center" rowspan="1" colspan="1">Mechanism</th><th align="center" rowspan="1" colspan="1">References</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="1" colspan="1">Hollow polymeric nanoparticles</td><td align="left" rowspan="1" colspan="1">MERS-CoV (Middle East Respiratory Syndrome Coronavirus)</td><td align="left" rowspan="1" colspan="1">STING agonist</td><td align="left" rowspan="1" colspan="1">Elicits antigen-specific T-cell response without triggering eosinophilic immunopathology</td><td align="left" rowspan="1" colspan="1">(<xref rid="B42" ref-type="bibr">Lin et al., 2019</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">SARS-S, MERS-S (MERS Spike protein nanoparticle)</td><td align="left" rowspan="1" colspan="1">SARS-CoV, MERS-CoV</td><td align="left" rowspan="1" colspan="1">Amphiphilic membrane protein aggregates</td><td align="left" rowspan="1" colspan="1">Production of high levels of neutralizing antibodies in case of homologous viruses and no response against heterologous viruses</td><td align="left" rowspan="1" colspan="1">(<xref rid="B21" ref-type="bibr">Coleman et al., 2014</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">MERS-S</td><td align="left" rowspan="1" colspan="1">MERS-CoV</td><td align="left" rowspan="1" colspan="1">Aluminium (alum)</td><td align="left" rowspan="1" colspan="1">Simultaneous T<sub>H1</sub> and T<sub>H2</sub> response in heterologous prime-boost</td><td align="left" rowspan="1" colspan="1">(<xref rid="B34" ref-type="bibr">Jung et al., 2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Gold nanoparticle</td><td align="left" rowspan="1" colspan="1">SARS-CoV</td><td align="left" rowspan="1" colspan="1">Gold nanoparticle</td><td align="left" rowspan="1" colspan="1">Induces strong IgG response</td><td align="left" rowspan="1" colspan="1">(<xref rid="B59" ref-type="bibr">Sekimukai, Iwata, and Shuetsu, 2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Spherical gold nanoparticles</td><td align="left" rowspan="1" colspan="1">Transmissible Gastroenteritis Virus (TGEV)</td><td align="left" rowspan="1" colspan="1">Gold nanoparticle</td><td align="left" rowspan="1" colspan="1">An increased concentration of Interleukins (ILs)</td><td align="left" rowspan="1" colspan="1">(<xref rid="B63" ref-type="bibr">Staroverov et al., 2019</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Aluminium nanoparticles</td><td align="left" rowspan="1" colspan="1">SARS-CoV, MERS-CoV</td><td align="left" rowspan="1" colspan="1">Alum</td><td align="left" rowspan="1" colspan="1">Increase in number of IFN and immunoglobulins, T<sub>H1</sub> and T<sub>H2</sub> Balance</td><td align="left" rowspan="1" colspan="1">(<xref rid="B91" ref-type="bibr">Wang N. et al., 2020</xref>)</td></tr></tbody></table></table-wrap><p>Because of limited side effects, lower dosage quantity and multiple targeting, combination drug therapeutics play a pivotal role in the treatment of COVID-19. Nanocarriers act as potential candidates for multi drug delivery which in turn useful for combination drug therapy (<xref rid="B23" ref-type="bibr">Destache et al., 2009</xref>; <xref rid="B61" ref-type="bibr">Shibata et al., 2013</xref>). The antigen delivering mode of nanoparticles to dendritic cells facilities T cell immunity (<xref rid="B32" ref-type="bibr">Joffre et al., 2012</xref>). Targeted drug delivery for the treatment of COVID-19 can be enhanced by the application of nanomaterials including nanospheres, nanocarriers, liposomes, lipid nanoparticles, nanophages and dendrimers (<xref rid="B78" ref-type="bibr">Witika et al., 2020</xref>). <xref ref-type="fig" rid="F3">Figure 3</xref> depicts the schematic illustration of a nano-based approach to combat COVID-19.</p><fig id="F3" position="float" orientation="portrait"><label>FIGURE 3</label><caption><p>A schematic illustration of nano-based approach to combat Covid-19.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fmolb-08-604447-g003.jpg"/></fig></sec></sec></sec><sec id="s3"><title>Present Status and Future Perspectives</title><p>Even though the antimicrobial drugs including chloroquine, remdesivir, lopinavir shows promising results against SARS-CoV-2 (<xref rid="B94" ref-type="bibr">Mainardes and Diedrich, 2020</xref>), it may cause side effects to some patients. The association of nano-carriers provides a necessary environment for the functioning of these drugs without any harmful effects (<xref rid="B12" ref-type="bibr">Campos et al., 2020</xref>). The existing antiviral drugs lack specificity and cause cytotoxicity and which are made to mimic Heparan Sulphate Proteoglycan (HSPG), the first step is virus-cell interaction, which are conserved regions for the ligands of the virus. Unlike invasive carriers, drug delivery of smart nano-carriers is based on the external stimuli like magnetic field or ultrasound (<xref rid="B31" ref-type="bibr">Jindal and Gopinath, 2020</xref>). Likewise the effective demonstration of nano-carriers in the treatment of Human Immunodeficiency Virus (HIV), Hepatitis, Influenza A virus etc., (<xref rid="B1" ref-type="bibr">Abd Elkodous et al., 2019</xref>; <xref rid="B51" ref-type="bibr">Negahdari et al., 2019</xref>; <xref rid="B38" ref-type="bibr">Kim et al., 2020</xref>), the existing drugs are being tested for the treatment of SARS-CoV-2 infection. Since SARS-CoV-2 infects the respiratory system, the drugs are administered through non-invasive methods. The aerosols administered without nano-carriers, may not bind with the target. Hence, nano-carrier mediated drug delivery is preferred for the successful binding with the target (<xref rid="B31" ref-type="bibr">Jindal and Gopinath, 2020</xref>).</p><p>The iron oxide nanoparticles approved by FDA for <italic toggle="yes">in vitro</italic> viral treatment was monitored for the discovery of treatment methods of SARS-CoV-2. The docking studies of iron oxide nanoparticles with the viral S protein of the SARS-CoV-2 exhibited better complex binding, which can be further improved in clinical trial stages (<xref rid="B2" ref-type="bibr">Abo-zeid et al., 2020</xref>). Several natural compounds have also been contributed to antiviral therapy. The inhibition of Hepatitis C virus into the hepatoblastoma cells was improved when curcumin loaded chitosan-based nanoparticles are used, it disturbs the viral membrane integrity (<xref rid="B47" ref-type="bibr">Loutfy et al., 2020</xref>). The IL-6 and IL-1&#946; mediators of the viral response were diminished when curcumin-based nanoparticles were employed for treating patients with SARS-CoV-2. IL-1&#946; is produced right after viral attachment and IL-6 on the progression of the infection. It is suggested to use nano-curcumin for COVID-19 (<xref rid="B68" ref-type="bibr">Valizadeh et al., 2020</xref>).</p><p>The application of silver nanoparticles for the treatment of Respiratory Syncytial Virus (RSV) has shown promising results in the mouse model, in which the nanoparticles tend to inhibit the viral replication in the host by binding to the viral glycoprotein and recruiting the neutrophils. Thus, silver nanoparticles reduce the spread of SARS-CoV-2 and are used to prevent the infected patient from ventilator-associated pneumonia (<xref rid="B50" ref-type="bibr">Morris et al., 2019</xref>; <xref rid="B30" ref-type="bibr">Issn and Sarkar 2020</xref>; <xref rid="B83" ref-type="bibr">Zachar, 2020</xref>). The toxicity caused due to the application of chloroquine and hydroxychloroquine for treating SARS-CoV-2 can be reduced by the application of noble nanoparticles (Au, Ag, Pt) (<xref rid="B56" ref-type="bibr">Rezaee et al., 2020</xref>). Currently, novel lipid nanoparticle encapsulates mRNA (mRNA-1273) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04283461">NCT04283461</ext-link>) is under clinical trial for SARS-CoV-2 by National Institute of Allergy and Infectious Disease (NIAID), United States. It is also suggested that combination of traditional interventions and western medicine for COVID-19 (<xref rid="B52" ref-type="bibr">Ni et al., 2020</xref>). China, Japan, South Korea and Singapore got relieved from the spreading because of Traditional Chinese Medicine (TCM) or Chinese Herbal Medicine (CHM) (<xref rid="B81" ref-type="bibr">Xu and Zhang 2020</xref>) and death rate is controlled to considerable extent. Peptide vaccines are considered as the most significant therapeutic compounds for viral infections (<xref rid="B5" ref-type="bibr">Agarwal and Gabrani, 2020</xref>; <xref rid="B11" ref-type="bibr">Brice and Diamond, 2020</xref>; <xref rid="B36" ref-type="bibr">Kalita et al., 2020</xref>). Further, novel delivery modes facilitate peptides as prominent vaccine candidates for COVID-19 (<xref rid="B24" ref-type="bibr">Di Natale et al., 2020</xref>).</p></sec><sec sec-type="conclusion" id="s4"><title>Conclusion</title><p>WHO is kept on track for the research and development of vaccines against SARS-CoV-2 across the world. Out of all the epidemics and pandemics, the vaccine development has been faster for SARS-CoV-2 due to its fast-paced spread throughout the world. Compared to other SARS virus vaccines that have reached clinical trials within 22 months&#8211;26 months, SARS-CoV-2 vaccine is the one in history that has reached the clinical trial phases within 3&#8211;6 months. But until an effective vaccine is formulated, it is better to control the pandemic using repurposed drugs.</p></sec></body><back><sec id="s5"><title>Author Contributions</title><p>KV, PS, VA and MS designed, searched, and analyzed the data and prepared draft figures and tables. KV, PS, DR, MS, prepared the manuscript draft with important intellectual input from HB, SR, KA, PB, CB, AP, KB and MS All authors approved the final manuscript.</p></sec><sec sec-type="COI-statement" id="s6"><title>Conflict of Interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec id="s7"><title>Supplementary Material</title><p>The Supplementary Material for this article can be found online at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fmolb.2021.604447/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fmolb.2021.604447/full#supplementary-material</ext-link>.</p><supplementary-material content-type="local-data" id="SM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="DataSheet1.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abd Elkodous</surname><given-names>M.</given-names></name><name name-style="western"><surname>El&#8208;Sayyad</surname><given-names>G. S.</given-names></name><name name-style="western"><surname>Nasser</surname><given-names>H. A.</given-names></name><name name-style="western"><surname>Elshamy</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Morsi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Abdelrahman</surname><given-names>I. Y.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Engineered nanomaterials as potential candidates for HIV treatment: between opportunities and challenges</article-title>. <source>J. Cluster Sci.</source><volume>8</volume>, <fpage>531</fpage>&#8211;<lpage>540</lpage>. <pub-id pub-id-type="doi">10.1007/s10876-019-01533-8</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abo-zeid</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ismail</surname><given-names>N. S.</given-names></name><name name-style="western"><surname>McLean</surname><given-names>G. R.</given-names></name><name name-style="western"><surname>Hamdy</surname><given-names>N. M.</given-names></name></person-group> (<year>2020</year>). <article-title>A molecular docking study repurposes FDA approved iron oxide nanoparticles to treat and control COVID-19 infection</article-title>. <source>Eur. J. Pharm. Sci.</source><volume>153</volume>, <fpage>105465</fpage>. <pub-id pub-id-type="doi">10.1016/j.ejps.2020.105465</pub-id><pub-id pub-id-type="pmid">32668312</pub-id><pub-id pub-id-type="pmcid">PMC7354764</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Acharya</surname><given-names>R.</given-names></name></person-group> (<year>2020</year>). <article-title>Prospective vaccination of COVID-19 using shRNA-plasmid-LDH nanoconjugate</article-title>. <source>Med. Hypotheses</source>, <volume>143</volume>, <fpage>110084</fpage>. <pub-id pub-id-type="doi">10.1016/j.mehy.2020.110084</pub-id><pub-id pub-id-type="pmid">32663741</pub-id><pub-id pub-id-type="pmcid">PMC7346779</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adams</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gonzalez-Duarte</surname><given-names>A.</given-names></name><name name-style="western"><surname>O&#8217;Riordan</surname><given-names>W. D.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C.- C.</given-names></name><name name-style="western"><surname>Ueda</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kristen</surname><given-names>A. V.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis</article-title>. <source>N. Engl. J. Med.</source><volume>379</volume>, <fpage>11</fpage>&#8211;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1056/nejmoa1716153</pub-id><pub-id pub-id-type="pmid">29972753</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agarwal</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gabrani</surname><given-names>R.</given-names></name></person-group> (<year>2020</year>). <article-title>Antiviral peptides: identification and validation</article-title>. <source>Int. J. Pept. Res. Ther.</source><volume>18</volume>, <fpage>1</fpage>&#8211;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1007/s10989-020-10072-0</pub-id><pub-id pub-id-type="pmcid">PMC7233194</pub-id><pub-id pub-id-type="pmid">32427225</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anselmo</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Modery-Pawlowski</surname><given-names>C. L.</given-names></name><name name-style="western"><surname>Menegatti</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vogus</surname><given-names>D. R.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>L. L.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Platelet-like nanoparticles: mimicking shape, flexibility, and surface biology of platelets to target vascular injuries</article-title>. <source>ACS Nano.</source><volume>8</volume>, <fpage>11243</fpage>&#8211;<lpage>11253</lpage>. <pub-id pub-id-type="doi">10.1021/nn503732m</pub-id><pub-id pub-id-type="pmid">25318048</pub-id><pub-id pub-id-type="pmcid">PMC4246005</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Badgett</surname><given-names>M. R.</given-names></name><name name-style="western"><surname>Auer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Carmichael</surname><given-names>L. E.</given-names></name><name name-style="western"><surname>Parrish</surname><given-names>C. R.</given-names></name></person-group> (<year>2002</year>). <article-title>Bull JJ (OctoberEvolutionary dynamics of viral attenuation</article-title>. <source>J. Virol.</source><volume>76</volume> (<issue>20</issue>), <fpage>10524</fpage>&#8211;<lpage>10529</lpage>. <pub-id pub-id-type="doi">10.1128/jvi.76.20.10524-10529.2002</pub-id><pub-id pub-id-type="pmid">12239331</pub-id><pub-id pub-id-type="pmcid">PMC136581</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Banchereau</surname><given-names>J.</given-names></name><name name-style="western"><surname>Steinman</surname><given-names>R. M.</given-names></name></person-group> (<year>1998</year>). <article-title>Dendritic cells and the control of immunity</article-title>. <source>Nature</source><volume>392</volume>, <fpage>245</fpage>&#8211;<lpage>252</lpage>. <pub-id pub-id-type="doi">10.1038/32588</pub-id><pub-id pub-id-type="pmid">9521319</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barh</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tiwari</surname><given-names>S.</given-names></name><name name-style="western"><surname>Silva Andrade</surname><given-names>B.</given-names></name><name name-style="western"><surname>Giovanetti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Almeida Costa</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kumavath</surname><given-names>R.</given-names></name></person-group> (<year>2020</year>). <article-title>Potential chimeric peptides to block the SARS-CoV-2 spike receptor-binding domain</article-title>. <source>F1000Res</source><volume>9</volume>, <fpage>576</fpage>. <pub-id pub-id-type="doi">10.12688/f1000research.24074.1</pub-id><pub-id pub-id-type="pmid">32802318</pub-id><pub-id pub-id-type="pmcid">PMC7411520</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beigel</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Tomashek</surname><given-names>K. M.</given-names></name><name name-style="western"><surname>Dodd</surname><given-names>L. E.</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Zingman</surname><given-names>B. S.</given-names></name><name name-style="western"><surname>Kalil</surname><given-names>A. C.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Remdesivir for the treatment of COVID-19&#8211;preliminary report</article-title>. <source>N. Engl. J. Med.</source><volume>383</volume> (<issue>10</issue>), <fpage>993</fpage>&#8211;<lpage>994</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMc2022236</pub-id><pub-id pub-id-type="pmid">32649078</pub-id></mixed-citation></ref><ref id="B93"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Borba</surname><given-names>M.</given-names></name><name name-style="western"><surname>Val</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sampaio</surname><given-names>V. S.</given-names></name><name name-style="western"><surname>Alexandre</surname><given-names>M.</given-names></name><name name-style="western"><surname>Melo</surname><given-names>G. C.</given-names></name><name name-style="western"><surname>Brito</surname><given-names>M.</given-names></name><etal/></person-group> Cloro Covid-19 Team (<year>2020</year>). <article-title>Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS&#8208;CoV&#8208;2) infection: a randomized clinical trial</article-title>. <source>JAMA Netw. Open</source><volume>3</volume> (<issue>4</issue>), <fpage>e208857</fpage>. <pub-id pub-id-type="pmid">32330277</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2020.8857</pub-id><pub-id pub-id-type="pmcid">PMC12124691</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brice</surname><given-names>D. C.</given-names></name><name name-style="western"><surname>Diamond</surname><given-names>G.</given-names></name></person-group> (<year>2020</year>). <article-title>Antiviral activities of human host defense peptides</article-title>. <source>Curr. Med. Chem.</source><volume>27</volume> (<issue>9</issue>), <fpage>1420</fpage>&#8211;<lpage>1443</lpage>. <pub-id pub-id-type="doi">10.2174/0929867326666190805151654</pub-id><pub-id pub-id-type="pmid">31385762</pub-id><pub-id pub-id-type="pmcid">PMC9008596</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Campos</surname><given-names>E. V. R.</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>A. E. S.</given-names></name><name name-style="western"><surname>de Oliveira</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Carvalho</surname><given-names>L. B.</given-names></name><name name-style="western"><surname>Guilger-Casagrande</surname><given-names>M.</given-names></name><name name-style="western"><surname>de Lima</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>How can nanotechnology help to combat COVID-19? opportunities and urgent need</article-title>. <source>J. Nanobiotechnol.</source><volume>18</volume>, <fpage>1</fpage>&#8211;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1186/s12951-020-00685-4</pub-id><pub-id pub-id-type="pmcid">PMC7474329</pub-id><pub-id pub-id-type="pmid">32891146</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19</article-title>. <source>N. Engl. J. Med.</source><volume>382</volume> (<issue>19</issue>), <fpage>1787</fpage>&#8211;<lpage>1799</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2001282</pub-id><pub-id pub-id-type="pmid">32187464</pub-id><pub-id pub-id-type="pmcid">PMC7121492</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>X.</given-names></name></person-group> (<year>2020</year>). <article-title>COVID-19: immunopathology and its implications for therapy</article-title>. <source>Nat. Rev. Immunol.</source><volume>2020</volume>, <fpage>1</fpage>&#8211;<lpage>2</lpage>. <pub-id pub-id-type="doi">10.1038/s41577-020-0308-3</pub-id><pub-id pub-id-type="pmcid">PMC7143200</pub-id><pub-id pub-id-type="pmid">32273594</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cavezzi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Troiani</surname><given-names>E.</given-names></name><name name-style="western"><surname>Corrao</surname><given-names>S.</given-names></name></person-group> (<year>2020</year>). <article-title>COVID-19: hemoglobin, iron, and hypoxia beyond inflammation. A narrative review</article-title>. <source>Clin. Pract.</source><volume>10</volume>, <fpage>1271</fpage>. <pub-id pub-id-type="doi">10.4081/cp.2020.1271</pub-id><pub-id pub-id-type="pmid">32509258</pub-id><pub-id pub-id-type="pmcid">PMC7267810</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chakravarthy</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vora</surname><given-names>A.</given-names></name></person-group> (<year>2020</year>). <article-title>Nanotechnology based antiviral therapeutics</article-title>. <source>Drug Deliv. Transl. Res.</source><volume>2020</volume>, <fpage>1</fpage>&#8211;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1007/s13346-020-00818-0</pub-id><pub-id pub-id-type="pmcid">PMC7398286</pub-id><pub-id pub-id-type="pmid">32748035</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yi</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Jianying</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ping</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhenshun</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jianyuan</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Favipiravir versus arbidol for COVID-19: a randomized clinical trial</article-title>. <source>medRxiv</source><volume>2020</volume>, <fpage>20037432</fpage>. <pub-id pub-id-type="doi">10.1101/2020.03.17.20037432v4</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chauhan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Madou</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Kalra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chopra</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ghosh</surname><given-names>D.</given-names></name><name name-style="western"><surname>Martinez-Chapa</surname><given-names>S. O.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Nanotechnology for COVID-19: therapeutics and vaccine research</article-title>. <source>ACS Nano.</source><volume>14</volume> (<issue>7</issue>), <fpage>7760</fpage>&#8211;<lpage>7782</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.0c04006</pub-id><pub-id pub-id-type="pmid">32571007</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Qu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>F.</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study</article-title>. <source>Lancet</source><volume>395</volume> (<issue>10223</issue>), <fpage>507</fpage>&#8211;<lpage>513</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(20)30211-7</pub-id><pub-id pub-id-type="pmid">32007143</pub-id><pub-id pub-id-type="pmcid">PMC7135076</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chourasia</surname><given-names>R.</given-names></name><name name-style="western"><surname>Padhi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chiring Phukon</surname><given-names>L.</given-names></name><name name-style="western"><surname>Abedin</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S. P.</given-names></name><name name-style="western"><surname>Rai</surname><given-names>A. K.</given-names></name></person-group> (<year>2020</year>). <article-title>A potential peptide from soy cheese produced using Lactobacillus delbrueckii WS4 for effective inhibition of SARS-CoV-2 main protease and S1 glycoprotein</article-title>. <source>Front. Mol. Biosci.</source><volume>7</volume>, <fpage>601753</fpage>. <pub-id pub-id-type="doi">10.3389/fmolb.2020.601753</pub-id><pub-id pub-id-type="pmid">33363209</pub-id><pub-id pub-id-type="pmcid">PMC7759660</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coleman</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y. V.</given-names></name><name name-style="western"><surname>Mu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>J. K.</given-names></name><name name-style="western"><surname>Massare</surname><given-names>M.</given-names></name><name name-style="western"><surname>Flyer</surname><given-names>D. C.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice</article-title>. <source>Vaccine</source><volume>32</volume> (<issue>26</issue>), <fpage>3169</fpage>&#8211;<lpage>3174</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2014.04.016</pub-id><pub-id pub-id-type="pmid">24736006</pub-id><pub-id pub-id-type="pmcid">PMC4058772</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: a retrospective cohort study</article-title>. <source>J. Infect.</source><volume>81</volume> (<issue>1</issue>), <fpage>e1</fpage>&#8211;<lpage>e5</lpage>. <pub-id pub-id-type="doi">10.1016/j.jinf.2020.03.002</pub-id><pub-id pub-id-type="pmcid">PMC7156152</pub-id><pub-id pub-id-type="pmid">32171872</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Destache</surname><given-names>C. J.</given-names></name><name name-style="western"><surname>Belgum</surname><given-names>T.</given-names></name><name name-style="western"><surname>Christensen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shibata</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dash</surname><given-names>A.</given-names></name></person-group> (<year>2009</year>). <article-title>Combination antiretroviral drugs in PLGA nanoparticle for HIV-1</article-title>. <source>BMC Infect. Dis.</source><volume>9</volume>, <fpage>198</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2334-9-198</pub-id><pub-id pub-id-type="pmid">20003214</pub-id><pub-id pub-id-type="pmcid">PMC2807870</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Di Natale</surname><given-names>C.</given-names></name><name name-style="western"><surname>La Manna</surname><given-names>S.</given-names></name><name name-style="western"><surname>De Benedictis</surname><given-names>I.</given-names></name><name name-style="western"><surname>Brandi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Marasco</surname><given-names>D.</given-names></name></person-group> (<year>2020</year>). <article-title>Perspectives in peptide-based vaccination strategies for syndrome coronavirus 2 pandemic</article-title>. <source>Front. Pharmacol.</source><volume>11</volume>, <fpage>578382</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2020.578382</pub-id><pub-id pub-id-type="pmid">33343349</pub-id><pub-id pub-id-type="pmcid">PMC7744882</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ellah</surname><given-names>N. H. A.</given-names></name><name name-style="western"><surname>Gad</surname><given-names>S. F.</given-names></name><name name-style="western"><surname>Muhammad</surname><given-names>K.</given-names></name><name name-style="western"><surname>Batiha</surname><given-names>G. E.</given-names></name><name name-style="western"><surname>Hetta</surname><given-names>H. F.</given-names></name></person-group> (<year>2020</year>). <article-title>Nanomedicine as a promising approach for diagnosis, treatment and prophylaxis against COVID-19</article-title>. <source>Nanomedicine</source><volume>15</volume>, <fpage>2085</fpage>&#8211;<lpage>2102</lpage>. <pub-id pub-id-type="doi">10.2217/nnm-2020-0247</pub-id><pub-id pub-id-type="pmid">32723142</pub-id><pub-id pub-id-type="pmcid">PMC7388682</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name></person-group> (<year>2020</year>). <article-title>Safety profile of the antiviral drug remdesivir: an update</article-title>. <source>Biomed. Pharmacother.</source><volume>130</volume>, <fpage>110532</fpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2020.110532</pub-id><pub-id pub-id-type="pmid">32707440</pub-id><pub-id pub-id-type="pmcid">PMC7373689</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gordon</surname><given-names>C. J.</given-names></name><name name-style="western"><surname>Tchesnokov</surname><given-names>E. P.</given-names></name><name name-style="western"><surname>Woolner</surname><given-names>E.</given-names></name><name name-style="western"><surname>Perry</surname><given-names>J. K.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>J. Y.</given-names></name><name name-style="western"><surname>Porter</surname><given-names>D. P.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency</article-title>. <source>J. Biol. Chem.</source><volume>295</volume> (<issue>20</issue>), <fpage>6785</fpage>&#8211;<lpage>6797</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.RA120.013679</pub-id><pub-id pub-id-type="pmid">32284326</pub-id><pub-id pub-id-type="pmcid">PMC7242698</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guan</surname><given-names>W.-J.</given-names></name><name name-style="western"><surname>Ni</surname><given-names>Z.-Y.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>W.-H.</given-names></name><name name-style="western"><surname>Ou</surname><given-names>C.-Q.</given-names></name><name name-style="western"><surname>He</surname><given-names>J.-X.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Clinical characteristics of coronavirus disease 2019 in China</article-title>. <source>N. Engl. J. Med.</source><volume>382</volume>, <fpage>1708</fpage>&#8211;<lpage>1720</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2002032</pub-id><pub-id pub-id-type="pmid">32109013</pub-id><pub-id pub-id-type="pmcid">PMC7092819</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Z.</given-names></name></person-group> (<year>2020</year>). <article-title>Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID&#8208;19): a systematic review and meta&#8208;analysis</article-title>. <source>J. Med. Virol.</source><volume>93</volume>, <fpage>481</fpage>. <pub-id pub-id-type="doi">10.1002/jmv.26256</pub-id><pub-id pub-id-type="pmid">32617989</pub-id><pub-id pub-id-type="pmcid">PMC7361300</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Issn</surname><given-names>O. P.</given-names></name><name name-style="western"><surname>Sarkar</surname><given-names>S.</given-names></name></person-group> (<year>2020</year>). <article-title>Silver nanoparticles with bronchodilators through nebulisation to treat COVID 19 patients</article-title>. <source>J. Curr. Med. Res. Opi.</source><volume>3</volume> (<issue>4</issue>), <fpage>449</fpage>&#8211;<lpage>450</lpage>. <pub-id pub-id-type="doi">10.15520/jcmro.v3i04.276</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jindal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gopinath</surname><given-names>P.</given-names></name></person-group> (<year>2020</year>). <article-title>Nanotechnology based approaches for combatting COVID-19 viral infection</article-title>. <source>Nano. Express.</source><volume>1</volume> (<issue>2</issue>), <fpage>022003</fpage>. <pub-id pub-id-type="doi">10.1088/2632-959x/abb714</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joffre</surname><given-names>O. P.</given-names></name><name name-style="western"><surname>Segura</surname><given-names>E.</given-names></name><name name-style="western"><surname>Savina</surname><given-names>A.</given-names></name><name name-style="western"><surname>Amigorena</surname><given-names>S.</given-names></name></person-group> (<year>2012</year>). <article-title>Cross-presentation by dendritic cells</article-title>. <source>Nat. Rev. Immunol.</source><volume>12</volume>, <fpage>557</fpage>&#8211;<lpage>569</lpage>. <pub-id pub-id-type="doi">10.1038/nri3254</pub-id><pub-id pub-id-type="pmid">22790179</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="webpage"><collab>Joint Formulary Committee</collab> (<year>2020</year>). <article-title>British national formulary 2020</article-title>. <comment>Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.medicinescomplete.com">http://www.medicinescomplete.com</ext-link></comment> (Accessed April 03, 2020). </mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jung</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19. The COVID-19 resource centre is hosted</article-title>. <source>Elsevier connect, the company&#8217;s public news and information</source>, <comment>January</comment>. </mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Juurlink</surname><given-names>D. N.</given-names></name></person-group> (<year>2020</year>). <article-title>Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection</article-title>. <source>CMAJ</source><volume>192</volume> (<issue>17</issue>), <fpage>E450</fpage>&#8211;<lpage>E453</lpage>. <pub-id pub-id-type="doi">10.1503/cmaj.200528</pub-id><pub-id pub-id-type="pmid">32269021</pub-id><pub-id pub-id-type="pmcid">PMC7207200</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kalita</surname><given-names>P.</given-names></name><name name-style="western"><surname>Padhi</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>K. Y. J.</given-names></name><name name-style="western"><surname>Tripathi</surname><given-names>T.</given-names></name></person-group> (<year>2020</year>). <article-title>Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2</article-title>. <source>Microb. Pathog.</source><volume>145</volume>, <fpage>104236</fpage>. <pub-id pub-id-type="doi">10.1016/j.micpath.2020.104236</pub-id><pub-id pub-id-type="pmid">32376359</pub-id><pub-id pub-id-type="pmcid">PMC7196559</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kallinteris</surname><given-names>N. L.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Blackwell</surname><given-names>C. E.</given-names></name><name name-style="western"><surname>von Hofe</surname><given-names>E.</given-names></name><name name-style="western"><surname>Humphreys</surname><given-names>R. E.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M.</given-names></name></person-group> (<year>2006</year>). <article-title>Ii-Key/MHC class II epitope hybrids: a strategy that enhances MHC class II epitope loading to create more potent peptide vaccines</article-title>. <source>Expert Opin. Biol. Ther.</source><volume>6</volume> (<issue>12</issue>), <fpage>1311</fpage>&#8211;<lpage>1321</lpage>. <pub-id pub-id-type="doi">10.1517/14712598.6.12.1311</pub-id><pub-id pub-id-type="pmid">17223739</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>Y. C.</given-names></name><name name-style="western"><surname>Dema</surname><given-names>B.</given-names></name><name name-style="western"><surname>Reyes-Sandoval</surname><given-names>A.</given-names></name></person-group> (<year>2020</year>). <article-title>COVID-19 vaccines: breaking record times to first-in-human trials</article-title>. <source>NPJ Vaccin.</source><volume>5</volume>, <fpage>34</fpage>. <pub-id pub-id-type="doi">10.1038/s41541-020-0188-3</pub-id><pub-id pub-id-type="pmcid">PMC7193619</pub-id><pub-id pub-id-type="pmid">32377399</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>LaBauve</surname><given-names>A. E.</given-names></name><name name-style="western"><surname>Rinker</surname><given-names>T. E.</given-names></name><name name-style="western"><surname>Noureddine</surname><given-names>A.</given-names></name><name name-style="western"><surname>Serda</surname><given-names>R. E.</given-names></name><name name-style="western"><surname>Howe</surname><given-names>J. Y.</given-names></name><name name-style="western"><surname>Sherman</surname><given-names>M. B.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Lipid-coated mesoporous silica nanoparticles for the delivery of the ML336 antiviral to inhibit encephalitic alphavirus infection</article-title>. <source>Sci. Rep.</source><volume>8</volume>, <fpage>13990</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-018-32033-w</pub-id><pub-id pub-id-type="pmid">30228359</pub-id><pub-id pub-id-type="pmcid">PMC6143628</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Joshi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Singhania</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ramsey</surname><given-names>K.</given-names></name><name name-style="western"><surname>Murthy</surname><given-names>A.</given-names></name></person-group> (<year>2014</year>). <article-title>Peptide vaccine: progress and challenges</article-title>. <source>Vaccines (Basel)</source><volume>2</volume> (<issue>3</issue>), <fpage>515</fpage>&#8211;<lpage>536</lpage>. <pub-id pub-id-type="doi">10.3390/vaccines2030515</pub-id><pub-id pub-id-type="pmid">26344743</pub-id><pub-id pub-id-type="pmcid">PMC4494216</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lian</surname><given-names>N.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Q.</given-names></name></person-group> (<year>2020</year>). <article-title>Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study</article-title>. <source>Clin. Microbiol. Infect.</source><volume>26</volume>, <fpage>917</fpage>&#8211;<lpage>921</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmi.2020.04.026</pub-id><pub-id pub-id-type="pmid">32344167</pub-id><pub-id pub-id-type="pmcid">PMC7182750</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>L. C. W.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C. Y.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>B. Y.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Agrawal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Algaissi</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Viromimetic STING agonist-loaded hollow polymeric nanoparticles for safe and effective vaccination against Middle East respiratory syndrome coronavirus</article-title>. <source>Adv. Funct. Mater</source>. <volume>29</volume> (<issue>28</issue>), <fpage>18076161</fpage>. <pub-id pub-id-type="doi">10.1002/adfm.201807616</pub-id><pub-id pub-id-type="pmcid">PMC7161765</pub-id><pub-id pub-id-type="pmid">32313544</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>S. C.</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>J. N.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>C. K.</given-names></name><name name-style="western"><surname>Chien</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y. S.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Structure-based stabilization of non-native protein-protein interactions of coronavirus nucleocapsid proteins in antiviral drug design</article-title>. <source>J. Med. Chem.</source><volume>63</volume>, <fpage>3131</fpage>&#8211;<lpage>3141</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.9b01913</pub-id><pub-id pub-id-type="pmid">32105468</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Hydroxychloroquine sulfate monograph for professionals&#8217;. The American society of health-system pharmacists. 20 March 2020. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection <italic toggle="yes">in vitro</italic>
</article-title>. <source>Cel Discov.</source><volume>6</volume>, <fpage>16</fpage>. <pub-id pub-id-type="doi">10.1038/s41421-020-0156-0</pub-id><pub-id pub-id-type="pmcid">PMC7078228</pub-id><pub-id pub-id-type="pmid">32194981</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X. J.</given-names></name></person-group> (<year>2020</year>). <article-title>Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines</article-title>. <source>J. Genet. Genomics</source><volume>47</volume> (<issue>2</issue>), <fpage>119</fpage>&#8211;<lpage>121</lpage>. <pub-id pub-id-type="doi">10.1016/j.jgg.2020.02.001</pub-id><pub-id pub-id-type="pmid">32173287</pub-id><pub-id pub-id-type="pmcid">PMC7128649</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lo</surname><given-names>M. K.</given-names></name><name name-style="western"><surname>Jordan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Arvey</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sudhamsu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shrivastava-Ranjan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hotard</surname><given-names>A. L.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses</article-title>. <source>Sci. Rep.</source><volume>7</volume>, <fpage>43395</fpage>. <pub-id pub-id-type="doi">10.1038/srep43395</pub-id><pub-id pub-id-type="pmid">28262699</pub-id><pub-id pub-id-type="pmcid">PMC5338263</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loutfy</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Elberry</surname><given-names>M. H.</given-names></name><name name-style="western"><surname>Ibrahim</surname><given-names>A. H.</given-names></name></person-group> (<year>2020</year>). <article-title>Antiviral activity of chitosan nanoparticles encapsulating curcumin against hepatitis C virus genotype 4a in human hepatoma cell lines</article-title>. <source>Int. J. Nanomedicine</source>. <volume>15</volume>, <fpage>2699</fpage>&#8211;<lpage>2715</lpage>. <pub-id pub-id-type="doi">10.2147/IJN.S241702</pub-id><pub-id pub-id-type="pmid">32368050</pub-id><pub-id pub-id-type="pmcid">PMC7184126</pub-id><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="retraction-forward" ext-link-type="pmc" xlink:href="PMC9270884"/></mixed-citation></ref><ref id="B94"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mainardes</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Diedrich</surname><given-names>C.</given-names></name></person-group> (<year>2020</year>). <article-title>The potential role of nanomedicine on COVID-19 therapeutics</article-title>. <source>Therap. Deliv.</source><fpage>7</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.4155/tde-2020-0069</pub-id><pub-id pub-id-type="pmcid">PMC7325497</pub-id><pub-id pub-id-type="pmid">32594863</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malonis</surname><given-names>R. J.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Vergnolle</surname><given-names>O.</given-names></name></person-group> (<year>2020</year>). <article-title>Peptide-based vaccines: current progress and future challenges</article-title>. <source>Chem. Rev.</source><volume>120</volume> (<issue>6</issue>), <fpage>3210</fpage>&#8211;<lpage>3229</lpage>. <pub-id pub-id-type="doi">10.1021/acs.chemrev.9b00472</pub-id><pub-id pub-id-type="pmid">31804810</pub-id><pub-id pub-id-type="pmcid">PMC7094793</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mckay</surname><given-names>P. F.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Blakney</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Samnuan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bouton</surname><given-names>C. R.</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine induces equivalent preclinical antibody titers and viral neutralization to recovered COVID-19 patients</article-title>. <source>Nat. Comm.</source><volume>11</volume>, <fpage>1</fpage>&#8211;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1101/2020.04.22.055608v1</pub-id><pub-id pub-id-type="pmcid">PMC7347890</pub-id><pub-id pub-id-type="pmid">32647131</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morris</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ansar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Speshock</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ivanciuc</surname><given-names>T.</given-names></name><name name-style="western"><surname>Qu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Casola</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Antiviral and immunomodulatory activity of silver nanoparticles in experimental RSV infection</article-title>. <source>Viruses</source><volume>11</volume> (<issue>8</issue>), <fpage>732</fpage>. <pub-id pub-id-type="doi">10.3390/v11080732</pub-id><pub-id pub-id-type="pmcid">PMC6723559</pub-id><pub-id pub-id-type="pmid">31398832</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Negahdari</surname><given-names>B.</given-names></name><name name-style="western"><surname>Darvishi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Saeedi</surname><given-names>A. A.</given-names></name></person-group> (<year>2019</year>). <article-title>Gold nanoparticles and hepatitis B virus</article-title>. <source>Artif. Cells Nanomed. Biotechnol.</source><volume>47</volume> (<issue>1</issue>), <fpage>469</fpage>&#8211;<lpage>474</lpage>. <pub-id pub-id-type="doi">10.1080/21691401.2018.1546185</pub-id><pub-id pub-id-type="pmid">30686057</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ni</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D. W.</given-names></name></person-group> (<year>2020</year>). <article-title>Combination of western medicine and Chinese traditional patent medicine in treating a family case of COVID-19</article-title>. <source>Front. Med.</source><volume>14</volume> (<issue>2</issue>), <fpage>210</fpage>&#8211;<lpage>214</lpage>. <pub-id pub-id-type="doi">10.1007/s11684-020-0757-x</pub-id><pub-id pub-id-type="pmid">32170559</pub-id><pub-id pub-id-type="pmcid">PMC7088740</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petros</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>DeSimone</surname><given-names>J. M.</given-names></name></person-group> (<year>2010</year>). <article-title>Strategies in the design of nanoparticles for therapeutic applications</article-title>. <source>Nat. Rev. Drug Discov.</source><volume>9</volume>, <fpage>615</fpage>&#8211;<lpage>627</lpage>. <pub-id pub-id-type="doi">10.1038/nrd2591</pub-id><pub-id pub-id-type="pmid">20616808</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="webpage"><collab>Pharmaceuticals and Medical Devices Agency</collab> (<year>2011</year>). <article-title>Evaluation and licensing division, pharmaceutical and Food safety BureauReport on the deliberation results&#8212;avigan. Japan</article-title><comment>Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.pmda.go.jp/files/000210319.pdf">www.pmda.go.jp/files/000210319.pdf</ext-link></comment>. </mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poduri</surname><given-names>R.</given-names></name><name name-style="western"><surname>Joshi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Jagadeesh</surname><given-names>G.</given-names></name></person-group> (<year>2020</year>). <article-title>Drugs targeting various stages of the SARS-CoV-2 life cycle: exploring promising drugs for the treatment of Covid-19</article-title>. <source>Cell. Signal.</source><volume>74</volume>, <fpage>109721</fpage>. <pub-id pub-id-type="doi">10.1016/j.cellsig.2020.109721</pub-id><pub-id pub-id-type="pmid">32711111</pub-id><pub-id pub-id-type="pmcid">PMC7375293</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rezaee</surname><given-names>P.</given-names></name><name name-style="western"><surname>Akbari</surname><given-names>M.</given-names></name><name name-style="western"><surname>Morad</surname><given-names>R.</given-names></name><name name-style="western"><surname>Koochaki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Maaz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jamshidi</surname><given-names>Z.</given-names></name></person-group> (<year>2020</year>). <article-title>First principle simulation of coated hydroxychloroquine on Ag, Au and Pt nanoparticle as a potential candidate for treatment of SARS-CoV-2 (COVID-19)</article-title>. <source>arXiv.</source><comment>arXiv:2006.02343</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-021-81617-6</pub-id><pub-id pub-id-type="pmcid">PMC7822900</pub-id><pub-id pub-id-type="pmid">33483539</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rismanbaf</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zarei</surname><given-names>S.</given-names></name></person-group> (<year>2020</year>). <article-title>Liver and kidney injuries in COVID-19 and their effects on drug therapy; a letter to editor</article-title>. <source>Arch. Acad. Emerg. Med.</source><volume>8</volume> (<issue>1</issue>), <fpage>e17</fpage>. <pub-id pub-id-type="doi">10.22037/aaem.v8i1.590</pub-id><pub-id pub-id-type="pmid">32185369</pub-id><pub-id pub-id-type="pmcid">PMC7075271</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saha</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>A. R.</given-names></name><name name-style="western"><surname>Bhattacharya</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S. S.</given-names></name><name name-style="western"><surname>Chakraborty</surname><given-names>C.</given-names></name></person-group> (<year>2020</year>). <article-title>Probable molecular mechanism of Remdesivir for the treatment of COVID-19: need to know more</article-title>. <source>Arch. Med. Res.</source><volume>51</volume> (<issue>6</issue>), <fpage>585</fpage>&#8211;<lpage>586</lpage>. <pub-id pub-id-type="doi">10.1016/j.arcmed.2020.05.001</pub-id><pub-id pub-id-type="pmid">32439198</pub-id><pub-id pub-id-type="pmcid">PMC7214327</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sekimukai</surname><given-names>H.</given-names></name><name name-style="western"><surname>Iwata</surname><given-names>N.</given-names></name><name name-style="western"><surname>Shuetsu</surname><given-names>Y.</given-names></name></person-group> (<year>2020</year>). <article-title>Gold nanoparticle&#8208;adjuvanted S protein induces a strong antigen&#8208;specific IgG response against severe acute respiratory syndrome&#8208;related coronavirus infection, but fails to induce protective antibodies and limit eosinophilic infiltration in lungs</article-title>. <source>Microbiol. Immunol.</source><volume>64</volume>, <fpage>33</fpage>&#8211;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1111/1348-0421.12754</pub-id><pub-id pub-id-type="pmid">31692019</pub-id><pub-id pub-id-type="pmcid">PMC7168429</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shannon</surname><given-names>A.</given-names></name><name name-style="western"><surname>Selisko</surname><given-names>B.</given-names></name><name name-style="western"><surname>Le</surname><given-names>N.</given-names></name><name name-style="western"><surname>Huchting</surname><given-names>J.</given-names></name><name name-style="western"><surname>Touret</surname><given-names>F.</given-names></name><name name-style="western"><surname>Piorkowski</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Favipiravir strikes the SARS-CoV-2 at its Achilles Heel, the RNA polymerase</article-title>. <source>bioRxiv: preprint Server Biol.</source><pub-id pub-id-type="doi">10.1101/2020.05.15.098731</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shibata</surname><given-names>A.</given-names></name><name name-style="western"><surname>McMullen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pham</surname><given-names>A.</given-names></name><name name-style="western"><surname>Belshan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sanford</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Polymeric nanoparticles containing combination antiretroviral drugs for HIV type 1 treatment</article-title>. <source>AIDS Res. Hum. Retroviruses</source><volume>29</volume>, <fpage>746</fpage>&#8211;<lpage>754</lpage>. <pub-id pub-id-type="doi">10.1089/aid.2012.0301</pub-id><pub-id pub-id-type="pmid">23289671</pub-id><pub-id pub-id-type="pmcid">PMC3636590</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shin</surname><given-names>M. D.</given-names></name><name name-style="western"><surname>Shukla</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>Y. H.</given-names></name><name name-style="western"><surname>Beiss</surname><given-names>V.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Ortega&#8208;Rivera</surname><given-names>O. A.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>COVID-19 vaccine development and a potential nanomaterial path forward</article-title>. <source>Nat. Nanotechnol.</source><volume>15</volume> (<issue>8</issue>), <fpage>646</fpage>&#8211;<lpage>655</lpage>. <pub-id pub-id-type="doi">10.1038/s41565-020-0737-y</pub-id><pub-id pub-id-type="pmid">32669664</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Staroverov</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Volkov</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Mezhenny</surname><given-names>P. V.</given-names></name><name name-style="western"><surname>Domnitsky</surname><given-names>I. Y.</given-names></name><name name-style="western"><surname>Fomin</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Kozlov</surname><given-names>S. V.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Prospects for the use of spherical gold nanoparticles in immunization</article-title>. <source>Appl. Microbiol. Biotechnol.</source><volume>103</volume>, <fpage>437</fpage>&#8211;<lpage>447</lpage>. <pub-id pub-id-type="doi">10.1007/s00253-018-9476-5</pub-id><pub-id pub-id-type="pmid">30402771</pub-id><pub-id pub-id-type="pmcid">PMC7080143</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steinman</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Banchereau</surname><given-names>J.</given-names></name></person-group> (<year>2007</year>). <article-title>Taking dendritic cells into medicine</article-title>. <source>Nature</source><volume>449</volume>, <fpage>419</fpage>&#8211;<lpage>426</lpage>. <pub-id pub-id-type="doi">10.1038/nature06175</pub-id><pub-id pub-id-type="pmid">17898760</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tahir ul Qamar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Alqahtani</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Alamri</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.-L.</given-names></name></person-group> (<year>2020</year>). <article-title>Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants</article-title>. <source>J. Pharm. Anal.</source><volume>10</volume>, <fpage>313</fpage>. <pub-id pub-id-type="doi">10.1016/j.jpha.2020.03.009</pub-id><pub-id pub-id-type="pmid">32296570</pub-id><pub-id pub-id-type="pmcid">PMC7156227</pub-id></mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Han</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2020a</year>). <article-title>Hydroxychloroquine in patients with COVID-19: an open-label, randomized control trial</article-title>. <source>medRxiv</source>. <pub-id pub-id-type="doi">10.1101/2020.04.10.20060558</pub-id></mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>B.</given-names></name><name name-style="western"><surname>He</surname><given-names>F.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>D.</given-names></name></person-group> (<year>2020b</year>). <article-title>AI-aided design of novel targeted covalent inhibitors against SARS-CoV-2</article-title>. <source>bioRxiv</source>. (Accessed April 07, 2020). <pub-id pub-id-type="doi">10.1101/2020.03.03.972133</pub-id><pub-id pub-id-type="pmcid">PMC9220321</pub-id><pub-id pub-id-type="pmid">35740872</pub-id></mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Valizadeh</surname><given-names>H.</given-names></name><name name-style="western"><surname>Abdolmohammadi&#8208;Vahid</surname><given-names>S.</given-names></name><name name-style="western"><surname>Danshina</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gencer</surname><given-names>M. Z.</given-names></name><name name-style="western"><surname>Ammari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sadeghi</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients</article-title>. <source>Int. Immunopharmacology</source><volume>89</volume>, <fpage>107088</fpage>. <pub-id pub-id-type="doi">10.1016/j.intimp.2020.107088</pub-id><pub-id pub-id-type="pmcid">PMC7574843</pub-id><pub-id pub-id-type="pmid">33129099</pub-id></mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Velavan</surname><given-names>T. P.</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>C. G.</given-names></name></person-group> (<year>2020</year>). <article-title>The COVID-19 epidemic</article-title>. <source>Trop. Med. Int. Health</source><volume>25</volume> (<issue>3</issue>), <fpage>278</fpage>&#8211;<lpage>280</lpage>. <pub-id pub-id-type="doi">10.1111/tmi.13383</pub-id><comment>Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/32052514/">https://pubmed.ncbi.nlm.nih.gov/32052514/</ext-link></comment>. <pub-id pub-id-type="pmid">32052514</pub-id><pub-id pub-id-type="pmcid">PMC7169770</pub-id></mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Villala&#237;n</surname><given-names>J.</given-names></name></person-group> (<year>2010</year>). <article-title>Membranotropic effects of arbidol, a broad anti-viral molecule, on phospholipid model membranes</article-title>. <source>J. Phys. Chem. B</source><volume>114</volume> (<issue>25</issue>), <fpage>8544</fpage>&#8211;<lpage>8554</lpage>. <pub-id pub-id-type="doi">10.1021/jp102619w</pub-id><pub-id pub-id-type="pmid">20527735</pub-id></mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) <italic toggle="yes">in vitro</italic>
</article-title>. <source>Cell Res.</source><volume>30</volume> (<issue>3</issue>), <fpage>269</fpage>&#8211;<lpage>271</lpage>. <pub-id pub-id-type="doi">10.1038/s41422-020-0282-0</pub-id><pub-id pub-id-type="pmid">32020029</pub-id><pub-id pub-id-type="pmcid">PMC7054408</pub-id></mixed-citation></ref><ref id="B91"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name></person-group> (<year>2020</year>). <article-title>Aluminum nanoparticles acting as a pulmonary vaccine adjuvant-delivery system (VADS) able to safely elicit robust systemic and mucosal immunity</article-title>. <source>J. Inorg. Organomet. Polym.</source><volume>30</volume>, <fpage>4203</fpage>&#8211;<lpage>4217</lpage>. <pub-id pub-id-type="doi">10.1007/s10904-020-01572-z</pub-id><pub-id pub-id-type="pmcid">PMC7210793</pub-id><pub-id pub-id-type="pmid">32395098</pub-id></mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>J.,</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zai</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name></person-group> (<year>2020</year>). <article-title>Homologous recombination within the spike glycoprotein of the newly identified coronavirus may boost cross-species transmission from snake to human</article-title>. <source>J. Med. Virol.</source><volume>92</volume>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jmv.25682</pub-id><pub-id pub-id-type="pmcid">PMC7138088</pub-id><pub-id pub-id-type="pmid">31967321</pub-id></mixed-citation></ref><ref id="B74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weinberger</surname><given-names>B.</given-names></name></person-group> (<year>2018</year>). <article-title>Adjuvant strategies to improve vaccination of the elderly population</article-title>. <source>Curr. Opin. Pharmacol.</source><volume>41</volume>, <fpage>34</fpage>&#8211;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1016/j.coph.2018.03.014</pub-id><pub-id pub-id-type="pmid">29677646</pub-id></mixed-citation></ref><ref id="B75"><mixed-citation publication-type="webpage"><collab>WHO-Draft landscape of COVID-19 candidate vaccines</collab> (<year>2021</year>). <article-title>WHO-Draft landscape of COVID-19 candidate vaccines</article-title>. <comment>Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines">https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines</ext-link></comment>. </mixed-citation></ref><ref id="B76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williamson</surname><given-names>B. N.</given-names></name><name name-style="western"><surname>Feldmann</surname><given-names>F.</given-names></name><name name-style="western"><surname>Schwarz</surname><given-names>B.</given-names></name><name name-style="western"><surname>Meade-White</surname><given-names>K.</given-names></name><name name-style="western"><surname>Porter</surname><given-names>D. P.</given-names></name><name name-style="western"><surname>Schulz</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2</article-title>. <source>bioRxiv</source>. <pub-id pub-id-type="doi">10.1101/2020.04.15.043166</pub-id><pub-id pub-id-type="pmcid">PMC7486271</pub-id><pub-id pub-id-type="pmid">32516797</pub-id></mixed-citation></ref><ref id="B77"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wit</surname><given-names>E.</given-names></name></person-group> (<year>2020</year>). <article-title>Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2</article-title>. <source>Nature</source><volume>585</volume> (<issue>7824</issue>), <fpage>273</fpage>&#8211;<lpage>276</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2423-5</pub-id><pub-id pub-id-type="pmid">32516797</pub-id><pub-id pub-id-type="pmcid">PMC7486271</pub-id></mixed-citation></ref><ref id="B78"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Witika</surname><given-names>B. A.</given-names></name><name name-style="western"><surname>Makoni</surname><given-names>P. A.</given-names></name><name name-style="western"><surname>Mweetwa</surname><given-names>L. L.</given-names></name><name name-style="western"><surname>Ntemi</surname><given-names>P. V.</given-names></name><name name-style="western"><surname>M. T. </surname><given-names>R.</given-names></name><name name-style="western"><surname>Mwila</surname><given-names>S. K. C.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Nano-biomimetic drug delivery vehicles: potential approaches for COVID-19 treatment</article-title>. <source>Molecules</source><volume>25</volume>, <fpage>5952</fpage>. <pub-id pub-id-type="doi">10.3390/molecules25245952</pub-id><pub-id pub-id-type="pmcid">PMC7765509</pub-id><pub-id pub-id-type="pmid">33339110</pub-id></mixed-citation></ref><ref id="B79"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wrapp</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Corbett</surname><given-names>K. S.</given-names></name><name name-style="western"><surname>Goldsmith</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>C. L.</given-names></name><name name-style="western"><surname>Abiona</surname><given-names>O.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation</article-title>. <source>Science</source><volume>367</volume> (<issue>6483</issue>), <fpage>1260</fpage>&#8211;<lpage>1263</lpage>. <pub-id pub-id-type="doi">10.1126/science.abb2507</pub-id><pub-id pub-id-type="pmid">32075877</pub-id><pub-id pub-id-type="pmcid">PMC7164637</pub-id></mixed-citation></ref><ref id="B80"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>S. C.</given-names></name></person-group> (<year>2020</year>). <article-title>Progress and concept for COVID-19 vaccine development</article-title>. <source>Biotechnol. J.</source><volume>15</volume> (<issue>6</issue>), <fpage>e2000147</fpage>. <pub-id pub-id-type="doi">10.1002/biot.202000147</pub-id><pub-id pub-id-type="pmid">32304139</pub-id><pub-id pub-id-type="pmcid">PMC7235517</pub-id></mixed-citation></ref><ref id="B81"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name></person-group> (<year>2020</year>). <article-title>Traditional Chinese medicine treatment of COVID-19</article-title>. <source>Complement. Ther. Clin. Pract.</source><volume>39</volume>, <fpage>101165</fpage>. <pub-id pub-id-type="doi">10.1016/j.ctcp.2020.101165</pub-id><pub-id pub-id-type="pmid">32379692</pub-id><pub-id pub-id-type="pmcid">PMC7118627</pub-id></mixed-citation></ref><ref id="B82"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ye</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Garc&#237;a-Sastre</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schotsaert</surname><given-names>M.</given-names></name><name name-style="western"><surname>De Geest</surname><given-names>B. G.</given-names></name></person-group> (<year>2020</year>). <article-title>Current status of COVID&#8208;19 (pre) clinical vaccine development</article-title>. <source>Angew. Chem. Int. Ed. Engl.</source> [<comment>Epub ahead of print</comment>]. <pub-id pub-id-type="doi">10.1002/anie.202008319</pub-id><pub-id pub-id-type="pmcid">PMC7405471</pub-id><pub-id pub-id-type="pmid">32663348</pub-id></mixed-citation></ref><ref id="B83"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zachar</surname><given-names>O.</given-names></name></person-group> (<year>2020</year>). <article-title>Formulations for COVID-19 early stage treatment via silver nanoparticles inhalation delivery at home and hospital</article-title>. <source>Scie.Open Pre.</source><volume>2020</volume>, <fpage>0</fpage>&#8211;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.14293/S2199-1006.1.SOR-.PPHBJEO.v1</pub-id></mixed-citation></ref><ref id="B84"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeltins</surname><given-names>A.</given-names></name></person-group> (<year>2013</year>). <article-title>Construction and characterization of virus-like particles: a review</article-title>. <source>Mol. Biotechnol.</source><volume>53</volume> (<issue>1</issue>), <fpage>92</fpage>&#8211;<lpage>107</lpage>. <pub-id pub-id-type="doi">10.1007/s12033-012-9598-4</pub-id><pub-id pub-id-type="pmid">23001867</pub-id><pub-id pub-id-type="pmcid">PMC7090963</pub-id></mixed-citation></ref><ref id="B85"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Honko</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Downs</surname><given-names>S. N.</given-names></name><name name-style="western"><surname>Vasquez</surname><given-names>J. H.</given-names></name><etal/></person-group><article-title>Cellular nanosponges inhibit SARS-CoV-2 infectivity</article-title>. <source>Nano Lett.</source><year>2020</year>, <volume>20</volume>, <fpage>5570</fpage>&#8211;<lpage>5574</lpage>. <pub-id pub-id-type="doi">10.1021/acs.nanolett.0c02278</pub-id><pub-id pub-id-type="pmid">32551679</pub-id><pub-id pub-id-type="pmcid">PMC7301960</pub-id></mixed-citation></ref><ref id="B86"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X. L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X. G.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name></person-group> (<year>2020</year>). <article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title>. <source>Nature</source><volume>579</volume> (<issue>7798</issue>), <fpage>270</fpage>&#8211;<lpage>273</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2012-7</pub-id><pub-id pub-id-type="pmid">32015507</pub-id><pub-id pub-id-type="pmcid">PMC7095418</pub-id></mixed-citation></ref><ref id="B87"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pomplun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Loftis</surname><given-names>A. R.</given-names></name><name name-style="western"><surname>Loas</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pentelute</surname><given-names>B. L.</given-names></name></person-group> (<year>2020</year>). <article-title>The first-in-class peptide binder to the SARS-CoV-2 spike protein</article-title>. <source>bioRxiv</source>. <pub-id pub-id-type="doi">10.1101/2020.03.19.999318</pub-id></mixed-citation></ref><ref id="B88"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>W.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>F.</given-names></name></person-group> (<year>2020a</year>). <article-title>Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2</article-title>. <source>Cel Discov.</source><volume>6</volume>, <fpage>1</fpage>&#8211;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1038/s41421-020-0153-3</pub-id><pub-id pub-id-type="pmcid">PMC7073332</pub-id><pub-id pub-id-type="pmid">32194980</pub-id></mixed-citation></ref><ref id="B89"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nussinov</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>F.</given-names></name></person-group> (<year>2020b</year>). <article-title>Artificial intelligence in COVID-19 drug repurposing</article-title>. <source>Lancet Digit. Health.</source><volume>2</volume> (<issue>5</issue>), <fpage>e667</fpage>&#8211;<lpage>e676</lpage>. <pub-id pub-id-type="doi">10.1016/S2589-7500(20)30192-8</pub-id><pub-id pub-id-type="pmid">32984792</pub-id><pub-id pub-id-type="pmcid">PMC7500917</pub-id></mixed-citation></ref><ref id="B90"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zumla</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>J. F.</given-names></name><name name-style="western"><surname>Azhar</surname><given-names>E. I.</given-names></name><name name-style="western"><surname>Hui</surname><given-names>D. S.</given-names></name><name name-style="western"><surname>Yuen</surname><given-names>K. Y.</given-names></name></person-group> (<year>2016</year>). <article-title>Coronaviruses - drug discovery and therapeutic options</article-title>. <source>Nat. Rev. Drug Discov.</source><volume>15</volume> (<issue>5</issue>), <fpage>327</fpage>&#8211;<lpage>347</lpage>. <pub-id pub-id-type="doi">10.1038/nrd.2015.37</pub-id><pub-id pub-id-type="pmid">26868298</pub-id><pub-id pub-id-type="pmcid">PMC7097181</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>